



(11) **EP 1 804 835 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Description Paragraph(s) 7, 15, 28, 35, 37, 41, 43, 44, 59, 64, 68, 71, 78, 84, 86, 93**  
**Claims EN 1, 4, 18, 28**
- (51) Int Cl.:  
**A61K 39/395** <sup>(2006.01)</sup> **C12P 21/04** <sup>(2006.01)</sup>  
**C12P 21/06** <sup>(2006.01)</sup> **C12N 5/00** <sup>(2006.01)</sup>  
**C07K 14/715** <sup>(2006.01)</sup> **C07H 21/04** <sup>(2006.01)</sup>  
**C12N 15/62** <sup>(2006.01)</sup>
- (86) International application number:  
**PCT/US2005/032320**
- (87) International publication number:  
**WO 2006/031689 (23.03.2006 Gazette 2006/12)**
- (48) Corrigendum issued on:  
**29.09.2010 Bulletin 2010/39**
- (45) Date of publication and mention of the grant of the patent:  
**09.06.2010 Bulletin 2010/23**
- (21) Application number: **05810409.2**
- (22) Date of filing: **13.09.2005**

(54) **MULTIMERIC CONSTRUCTS**  
MULTIMERE KONSTRUKTE  
CONSTRUCTIONS MULTIMERIQUES

- (84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR**
- (30) Priority: **13.09.2004 US 608887 P**  
**04.03.2005 US 658209 P**
- (43) Date of publication of application:  
**11.07.2007 Bulletin 2007/28**
- (60) Divisional application:  
**10165159.4 / 2 229 956**
- (73) Proprietor: **GENZYME CORPORATION**  
**Cambridge, MA 02142 (US)**
- (72) Inventors:  
• **SCARIA, Abraham**  
**Framingham, MA 01701 (US)**  
• **PECHAN, Peter**  
**Brookline, MA 02446 (US)**  
• **WADSWORTH, Samuel**  
**Shewsbury, MA 01545 (US)**
- (74) Representative: **Adams, Harvey Vaughan John**  
**Mathys & Squire LLP**  
**120 Holborn**  
**London**  
**EC1N 2SQ (GB)**
- (56) References cited:  
**WO-A-00/75319 US-A1- 2003 092 604**
- **HOLASH JOCELYN ET AL: "VEGF-Trap: A VEGF blocker with potent antitumor effects"**  
**PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, vol. 99, no. 17, 20 August 2002 (2002-08-20), pages 11393-11398, XP002391854 ISSN: 0027-8424**
  - **VANGELISTA LUCA ET AL: "A minimal receptor-Ig chimera of human FcepsilonRI alpha-chain efficiently binds secretory and membrane IgE"**  
**PROTEIN ENGINEERING, vol. 15, no. 1, January 2002 (2002-01), pages 51-57, XP002484236 ISSN: 0269-2139**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 804 835 B9**

- OLAFSEN TOVE ET AL: "Characterization of engineered anti-p185HER-2 (scFv-CH3)<sub>2</sub> antibody fragments (minibodies) for tumor targeting" **PROTEIN ENGINEERING DESIGN & SELECTION**, vol. 17, no. 4, April 2004 (2004-04), pages 315-323, XP002484237 ISSN: 1741-0126
- HU S-Z ET AL: "MINIBODY: A NOVEL ENGINEERED ANTI-CARCINOEMBRYONIC ANTIGEN ANTIBODY FRAGMENT (SINGLE-CHAIN FV-CH3) WHICH EXHIBITS RAPID, HIGH-LEVEL TARGETING OF XENOGRAFTS" **CANCER RESEARCH**, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 56, no. 13, 1 July 1996 (1996-07-01), pages 3055-3061, XP000645454 ISSN: 0008-5472
- AFANASIEVA T A ET AL: "Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy" **GENE THERAPY**, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 10, no. 21, 1 October 2003 (2003-10-01), pages 1850-1859, XP002334755 ISSN: 0969-7128

**Description**

## FIELD OF THE INVENTION

5 **[0001]** The invention relates to recombinantly constructed proteins useful for treating pathological neovascularization, e.g., asthma, arthritis, cancer, and macular degeneration.

## BACKGROUND OF THE INVENTION

10 **[0002]** Pathological neovascularization is a key component of diseases like wet age-related macular degeneration (AMD), proliferative diabetic retinopathy, rheumatoid arthritis, osteoarthritis, and asthma. It also plays an important role in growth and spread of tumors. Neovascularization is regulated by an exquisite balance of pro- and anti-angiogenic factors.

15 **[0003]** Vascular endothelial growth factor (VEGF) is known to be necessary for neovascularization. Inhibition of VEGF activity has been shown to inhibit neovascularization in animal models of AMD, arthritis and in various tumor models. Methods used to inhibit VEGF activity include antibodies, receptor fusion proteins, peptides and small molecules.

20 **[0004]** VEGF-R1 (Flt-1) and VEGF-R2 (KDR) proteins have been shown to bind VEGF with high affinity. Both Flt-1 and KDR have seven Ig-like domains in their extracellular region. Domain 2 has been shown to be essential for VEGF binding. Fusions of each of the full-length, soluble receptor (domains 1-7) and domains 1-3 to IgG Fc bind VEGF efficiently. IgG Fc fusions to Ig-like domain 2 alone was, however, incapable of binding VEGF, as was a combination of Ig-like domain 1 and 2. Davis-Smyth, 1996. Therefore, Ig-like domains 1 and 3 seem to be required along with domain 2 for efficient VEGF binding.

25 **[0005]** Holash et al (2002) Proc. Natl. Acad. Sci. vol. 99(17): 11393-11398 discloses further fusion polypeptides comprising portions of the VEGF-R1 receptor fused to the Fc portion of the human IgG1 heavy chain. Vangelista et al (2002) Protein Engineering vol. 15(1): 51-57 discloses a fusion polypeptide in which the two extracellular domains of the human FcεRI α-chain are fused to the dimerizing C-terminal domain of the human IgG1 heavy chain.

## BRIEF SUMMARY OF THE INVENTION

30 **[0006]** According to one aspect of the present disclosure, a fusion protein is provided. The fusion protein has the formula X-Y-Z. X comprises a polypeptide selected from the group consisting of an extracellular receptor, an antibody variable region, a cytokine, a chemokine, and a growth factor. Y consists essentially of a 5 - 25 amino acid residue polypeptide. Z is a CH3 region of an IgG heavy chain molecule.

35 **[0007]** Another aspect of the present disclosure is a polypeptide of the formula X-Y-Z. X comprises a polypeptide selected from the group consisting of an extracellular receptor, an antibody variable region, a cytokine, a chemokine, and a growth factor. Y consists essentially of a linker moiety which provides the spatial separation of 5-25 amino acid residue. Z is a CH3 region of an IgG heavy chain molecule.

40 **[0008]** Yet another aspect of the present disclosure is a fusion protein of the formula X-Y-Z. X comprises a polypeptide selected from the group consisting of an extracellular receptor, an antibody variable region, a cytokine, a chemokine, and a growth factor. Y consists essentially of a 5 - 25 amino acid residue polypeptide. Z is an Fc portion of an antibody molecule.

45 **[0009]** A fusion protein of the formula X-Y-Z is also provided by the present disclosure. X comprises a polypeptide selected from the group consisting of an extracellular receptor, an antibody variable region, a cytokine, a chemokine, and a growth factor. Y consists essentially of a linker moiety which provides the spatial separation of 5-25 amino acid residues. Z is an Fc portion of an antibody molecule.

50 **[0010]** Still another aspect of the present disclosure is a method of multimerizing a polypeptide X. A polypeptide X is linked to a polypeptide Z via a polypeptide Y to form polypeptide XYZ. X comprises a polypeptide selected from the group consisting of an extracellular receptor, an antibody variable region, a cytokine, a chemokine, and a growth factor. Y consists essentially of a 5 - 25 amino acid residue polypeptide. Z is a CH3 region of an IgG heavy chain molecule. Polypeptide XYZ which is formed multimerizes.

55 **[0011]** Yet another aspect of the present disclosure provides a method of multimerizing a polypeptide X. Polypeptide X is linked to a polypeptide Z via a moiety Y to form polymer XYZ. X comprises a polypeptide selected from the group consisting of an extracellular receptor, an antibody variable region, a cytokine, a chemokine, and a growth factor. Y consists essentially of a linker moiety which provides the spatial separation of 5-25 amino acid residues. Z is a CH3 region of an IgG heavy chain molecule. Polypeptide XYZ which is so formed multimerizes.

**[0012]** In one aspect of the present disclosure a nucleic acid molecule is provided. The nucleic acid molecule encodes a fusion protein which comprises an Ig-like domain 2 of VEGF-R1 (Flt-1); a linker, and a multimerization domain. The fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 2, 8, 21, 23, and 25.

**[0013]** In another aspect of the present disclosure a fusion protein is provided. The fusion protein comprises an Ig-like domain 2 of VEGF-R1 (Flt-1), a linker, and a multimerization domain. The fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 2, 8, 21, 23, and 25.

**[0014]** In another aspect of the present disclosure an *in vitro* method is provided. A nucleic acid molecule is delivered to an isolated mammalian cell. The nucleic acid molecule encodes a fusion protein which comprises an Ig-like domain 2 of VEGF-R1 (Flt-1); a linker; and a multimerization domain. The fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 2, 8, 21, 23, and 25. Expression of the fusion protein is controlled by a promoter. A cell is formed which expresses a fusion protein.

**[0015]** Still another aspect of the present disclosure is a method for delivering a fusion protein to a mammal. A mammalian cell which expresses the fusion protein is delivered to a mammal. The cell expresses and secretes the fusion protein thereby supplying the fusion protein to the mammal. The fusion protein comprises an Ig-like domain 2 of VEGF-R1 (Flt-1), a linker, and a multimerization domain. The fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 2, 8, 21, 23, and 25.

**[0016]** Another aspect of the present disclosure is a method for supplying a fusion protein to a mammal. A fusion protein which comprises an Ig-like domain 2 of VEGF-R1 (Flt-1), a linker, and a multimerization domain is delivered to a mammal. The fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 2, 8, 21, 23, and 25. Alternatively, a nucleic acid construct which encodes said fusion protein can be delivered to the mammal, whereby the fusion protein is expressed by the mammal.

**[0017]** These and other aspects of the present disclosure, which will be described in more detail below, provide the art with methods and agents for treating diseases related to vascular proliferation and inflammation. The agents may provide increased stability and bioavailability relative to natural forms of the proteins.

**[0018]** Now a part of the disclosure that is contained herein provides the aspects and embodiments of the present invention. More particularly, a first aspect of the present invention provides a fusion protein of the formula X-Y-Z, wherein: X comprises the Ig-like domain 2 of VEGF-R1 but lacks the Ig-like domains 1 and 3 of VEGF-R1, with said Ig-like domain 2 of VEGF-R1 being covalently linked to moiety Z via moiety Y; Y consists of a 5 - 25 amino acid residue polypeptide; and Z is a CH3 region of an IgG heavy chain molecule or an Fc portion of an antibody molecule.

**[0019]** In a related aspect, the present invention provides a composition comprising this fusion protein of the invention, which composition further comprises one or more pharmaceutically acceptable excipients or carriers.

**[0020]** In a further aspect, the present invention provides a method of multimerizing a polypeptide X, the method comprising: linking a polypeptide X to a polypeptide Z via a polypeptide Y to form a polypeptide XYZ, wherein: X comprises the Ig-like domain 2 of VEGF-R1 but lacks the Ig-like domains 1 and 3 of VEGF-R1, with said Ig-like domain 2 of VEGF-R1 being covalently linked to polypeptide Z via polypeptide Y; Y consists of a 5 - 25 amino acid residue polypeptide; and Z is a CH3 region of an IgG heavy chain molecule or an Fc portion of an antibody molecule; whereby the polypeptide XYZ multimerizes.

**[0021]** In yet further aspects, the present invention provides a nucleic acid molecule which encodes the fusion protein of the present invention, a vector which comprises said nucleic acid molecule, a mammalian cell which comprises the nucleic acid molecule, and an *in vitro* method comprising delivering the nucleic acid molecule to an isolated mammalian cell so as to form a cell which expresses said fusion protein.

**[0022]** In still further aspects, the present invention provides the fusion protein, nucleic acid, vector or mammalian cell of the present invention, for use in treating a mammal. In one embodiment, the mammal has wet age-related macular degeneration or proliferative diabetic retinopathy. In another embodiment, the mammal has cancer. In another embodiment, the mammal has rheumatoid arthritis. In another embodiment, the mammal has asthma. In another embodiment, the mammal has osteoarthritis.

**[0023]** Additional aspects and embodiments of the present invention are set out in the appended claims.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0024]** Fig. 1. Flexible region of 9-Gly linker in D2-9Gly-Fc construct. The predicted relative flexibility by Karpus and Schultz (1985) method shows the polyglycine 9-mer (9-Gly) linker (aa 94 to 103) in D2-9Gly-Fc protein as a region with greater flexibility than the average (>1) as compared to D2-Fc construct that does not contain 9-Gly linker. Both fusion proteins contain identical amino acid sequences enclosed in boxes: sp - signal peptide (aa -24 to -1), Flt-1 domain 2 (aa 1 to 93) and IgG1-Fc residues (244 aa). The arrow represents the signal peptidase cleavage site as predicted using the SignalP V2.0 program (Nielsen et al., 1997).

**[0025]** Fig. 2. Biological activity of D2-9Gly-Fc vs. D2-Fc. 293 cells were grown in the starvation media (M199 + 5% FCS) and transfected with plasmids containing D2-9Gly-Fc and D2-Fc expression cassettes under control of CMV promoter. Conditioned media (CM) was collected 72 h later. HUVECs were seeded into 96 well plate (2E3 cells/well) in starvation media + VEGF (10 ng/mL) and 50 ul CM plus VEGF (10 ng/mL) was added 24 h later. The controls (+/- VEGF) were incubated with CM from the control pEGFP (Clontech; pEGFP carries a red-shifted variant of wild-type green

fluorescent protein (GFP) which has been optimized for brighter fluorescence and higher expression in mammalian cells) plasmid transfection. The positive control was treated with 50 ng of Flt-1-IgG recombinant protein (R&D Systems). The HUVECs were assayed for proliferation 3 days post treatment using CellTiter 96<sup>®</sup> AQueous reagent (Promega). The data represent the means of the average values of OD<sub>490</sub> of two experiments each assayed in triplicates.

5 **[0026]** Fig. 3. Western blot analysis of D2-9Gly-Fc and D2-Fc. The size of both D2-9Gly-Fc and D2-Fc proteins appears to be twice as large while migrating in non-reducing gel as compared to migration in reducing gel. The proteins were loaded from the conditioned media following 293 cell transfection of plasmids expressing D2-9Gly-Fc and D2-Fc were separated by SDS-electrophoresis and transferred to PVDF membrane. The blot was probed with goat anti-human anti-IgG1 Fc and rabbit anti-goat IgG-HRP antibodies.

10 **[0027]** Fig. 4. sFlt-1 hybrid proteins containing 9Gly linker and VEGF Ex3. Structure comparison of D2-9Gly-Ex3/CH3 to previously constructed proteins. All three proteins contain identical amino acid sequence of Flt-1 domain 2, consisting of 24 aa of Flt-1 signal peptide and 93 aa of Flt-1 domain 2. D2-9Gly-Ex3/CH3 contains 9 aa of 9Gly linker, 14 aa of VEGF Ex3 and 120 aa of the CH3 region of human IgG1 heavy chain Fc.

15 **[0028]** Fig. 5. Biological activity of D2-9Gly-Ex3/CH3 vs. D2-9Gly-Fc. Protein D2-9Gly-Ex3/CH3, where domain 2 is connected to the CH3 region through 9Gly linker and VEGF Ex 3, is also efficiently inhibiting VEGF-dependent HUVECs proliferation as compared to control proteins D2-9Gly-Fc and D2-Fc. 50 ng of the recombinant Flt-1-IgG (R&D Systems) was used as a control.

20 **[0029]** Fig. 6. HUVECs proliferation assay comparing D2-(Gly<sub>4</sub>Ser)<sub>3</sub>-Fc protein activity with D2-9Gly-Fc and D2-9Gly-Ex3/CH3.

25 **[0030]** Fig. 7. Western blot Proteins (non-reduced and reduced) from conditioned medium of transfected 293 cells (15 ul of CM) with plasmids expressing (1): D2-9Gly-Fc; (2): D2-(G<sub>4</sub>S)<sub>3</sub>-Fc and (3) - EGFP proteins were separated by SDS-electrophoresis and transferred to PVDF membrane. The blot was probed with goat anti-human IgG1 Fc and rabbit anti-goat IgG-HRP antibodies.

30 **[0031]** Fig. 8. Combinations of proteins with/without 9Gly linker or VEGF Ex3. Structure comparison of three novel proteins with or without 9Gly linker and/or VEGF Ex3, D2-9Gly-CH3, D2-CH3 and D2-Ex3/CH3.

35 **[0032]** Fig. 9. HUVECs proliferation assay with the Flt-1(D2) constructs with 9Gly, Ex3 and CH3 combinations. Conditioned media from 293 cells (5 ul) containing proteins D2-Ex3/CH3, D2-9Gly-CH3 and D2-CH3 were compared to D2-9Gly-Fc and D2-9Gly-Ex3/CH3.

40 **[0033]** Fig. 10 Western blot 293 cells were transfected with plasmids expressing: (1) D2-9Gly-Fc; (2) D2-9Gly-CH3 (52/26 kDa); and (3) D2-CH3 (50/25 kDa). Proteins from 293 cells conditioned medium (15 ul of CM non-reduced and/or reduced) were separated by SDS-electrophoresis and transferred to PVDF membrane. The blot was probed with anti-human VEGF-R1 HRP conjugate (R&D Systems).

45 **[0034]** Fig. 11. VEGF "in vitro" binding assay. Conditioned media from 293 cells containing known concentrations of both D2-9Gly-Fc and Flt-1 D(1-3) control soluble receptors (ranging in concentrations from 0.29 -150 pM) were serially diluted and mixed with 10 pM VEGF. The amount of unbound VEGF was then measured by ELISA. D2-9Gly-Fc binds VEGF with higher affinity than all other constructs. "n" represents the number of independent experiments (transfection and binding assay).

50 **[0035]** Fig. 12. The binding kinetics of the soluble Flt-1 constructs were measured by surface plasmon resonance with a BIAcore instrument. sFlt-1 constructs were immobilized onto a sensor chip, and VEGF165 was injected at concentrations ranging from 0.2 to 15 nM. The sensorgrams were evaluated using the BIA Evaluation program, the rate constants K<sub>a</sub> and K<sub>d</sub> were determined and the dissociation constant (K<sub>D</sub>) calculated from the ratio of K<sub>d</sub>/K<sub>a</sub> = K<sub>D</sub>. The lower K<sub>D</sub> value means better affinity.

55 **[0036]** Fig. 13A-13C. Fig 13A shows expression levels of Flt-1 constructs having various linkers. Fig. 13B shows dimerization or multimerization of Flt-1 constructs having various linkers and a CH3 moiety of Fc of IgG1. The difference between the non-reduced and the reduced conditions indicates that the proteins had multimerized. Fig. 13C shows the inhibitory bioactivity of indicated Flt-1 constructs present in condition medium in a HUVEC proliferation assay in the presence of VEGF. Each of the constructs demonstrated inhibitory activity approaching proliferation levels of the HUVEC in the absence of VEGF.

**[0037]** Fig. 14. Using a murine oxygen-induced retinopathy (OIR) model of retinal neovascularization (NV), one of the Flt-1 constructs was administered to the mouse eyes and neovascularization was determined. The mice were exposed to hyperoxic conditions. The number of neovascular events was determined in the treated eyes compared to the events in the untreated eyes of the same animals. The animal was considered a "responder" if there was a greater than 50% reduction in neovascular events.

## DETAILED DESCRIPTION OF THE INVENTION

**[0038]** It is a discovery of the present inventors that a Flt-1 Ig-like domain 2 without domains 1 and 3 is capable of efficiently binding VEGF and inhibiting VEGF-dependent endothelial cell proliferation. Domain 2 can be covalently linked

to a multimerization domain via a linker. Linkers are typically polypeptide chains. The length of the chain may be 6, 7, 9, 11, 13, 15 or more amino acid residues, but typically is between 5 and 25 residues. Depending upon the length and side chain composition, a linker may have but need not have greater than average flexibility. Flexibility can be calculated using algorithms known in the art. Multimerization domains are those portions of multimeric proteins which promote the association of subunits to form, for example, dimers, trimers, tetramers, etc. Suitable recombinant proteins for efficiently binding VEGF and/or inhibiting VEGF-dependent endothelial cell proliferation are selected from the group consisting of SEQ ID NO: 2, 8, 21, 23, and 25.

**[0039]** Moreover, the inventors have found that the multimerization domains and linkers can be used with a variety of other proteins or portions of proteins to induce multimerization. Such proteins may be those which bind to ligand or receptor only when multimerized, or may be those whose binding affinity is enhanced when multimerized. Suitable proteins for multimerization include extracellular receptors (which include portions thereof), antibody variable regions, cytokines, chemokines, and growth factors. Suitable proteins include tyrosine kinase receptors and serine threonine kinase receptors. Specific examples of extracellular receptors include EGF-receptor, G protein coupled receptors, FGF receptor, Fc receptors, T cell receptors, etc. Examples of antibody variable regions include Fab, F(ab')<sub>2</sub>, and ScFv. Examples of cytokines include GM-CSF, IL-1 $\alpha$ , IL-1 $\beta$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-18, IL-21, IL-23, IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , MIP-1 $\alpha$ , MIP-1 $\beta$ , TGF- $\beta$ , TNF $\alpha$ , and TNF- $\beta$ . Examples of chemokines include BCA-1 / BLC, BRAK, Chemokine CC-2, CTACK, CXCL-16, ELC, ENA, ENA-74, ENA-78, Eotaxin, Exodus-2, Fractalkine, GCP-2, GRO, GRO alpha (MGSa), GRO-beta, GRO-gamma, HCC-1, HCC-4, 1-309, IP-10, I-TAC, LAG-1, LD78-beta, LEC / NCC-4, LL-37, Lymphotactin, MCP, MCAF (MCP-1), MCP-2, MCP-3, MCP-4, MDC, MDC, MDC-2, MDC-4, MEC / CCL28, MIG, MIP, MIP-1 alpha, MIP-1 beta, MIP-1 delta, MIP-3 / MPIF-1, MIP-3 alpha, MIP-3 beta, MIP-4 (PARC), MIP-5, NAP-2, PARC, PF-4, RANTES, RANTES-2, SDF-1 alpha, SDF-1 beta, TARC, and TECK. Examples of growth factors include Human Amphiregulin, Human Angiogenesis Proteins, Human ACE, Human Angiogenin, Human Angiopoietin, Human Angiostatin, Human Betacellulin, Human BMP, Human BMP-13 / CDMP-2, Human BMP-14 / CDMP-1, Human BMP-2, Human BMP-3, Human BMP-4, Human BMP-5, Human BMP-6, Human BMP-7, Human BMP-8, Human BMP-9, Human Colony Stimulating Factors, Human flt3-Ligand, Human G-CSF, Human GM-CSF, Human M-CSF, Human Connective Tissue Growth Factor, Human Cripto-1, Human Cryptic, Human ECGF, Human EGF, Human EG-VEGF, Human Erythropoietin, Human Fetuin, Human FGF, Human FGF-1, Human FGF-10, Human FGF-16, Human FGF-17, Human FGF-18, Human FGF-19, Human FGF-2, Human FGF-20, Human FGF-3, Human FGF-4, Human FGF-5, Human FGF-6, Human FGF-7 / KGF, Human FGF-8, Human FGF-9, Human FGF-acidic, Human FGF-basic, Human GDF-11, Human GDF-15, Human Growth Hormone Releasing Factor, Human HB-EGF, Human Heregulin, Human HGF, Human IGF, Human IGF-I, Human IGF-II, Human Inhibin, Human KGF, Human LCGF, Human LIF, Human Miscellaneous Growth Factors, Human MSP, Human Myostatin, Human Myostatin Propeptide, Human Nerve Growth Factor, Human Oncostatin M, Human PD-ECGF, Human PDGF, Human PDGF (AA Homodimer), Human PDGF (AB Heterodimer), Human PDGF (BB Homodimer), Human PDGF (CC Homodimer), Human PIGF, Human PIGF, Human PIGF-1, Human PIGF-2, Human SCF, Human SMDF, Human Stem Cell Growth Factor, Human SCGF-alpha, Human SCGF-beta, Human Thrombopoietin, Human Transforming Growth Factor, Human TGF-alpha, Human TGF-beta, and Human VEGF.

**[0040]** Flt-1 receptor protein has an extracellular portion which comprises seven Ig-like domains. These are located at residue numbers 32...123, 151...214, 230...327, 335...421, 428...553, 556...654, and 661...747 of Genbank accession no. P17948, see also SEQ ID NO: 15. Residue numbers 1-26 comprise a signal sequence. Flt-1 protein is encoded by the DNA sequence shown at Genbank accession no. NM\_002019 (SEQ ID NO: 14).

**[0041]** Multimerization domains that can be used in accordance with the present disclosure are known in the art. Sequences of the Fc portion of IgG1 or IgG2 gamma heavy chain can be used, for example, CH3 alone (aa 371-477) or both of CH2 and CH3 domains (aa 247-477). Fc portion of Ig molecules is that which is obtained by cleavage of whole antibody molecules with the enzyme papain. Other means can be used to obtain these portions. For the IgG1 gamma heavy chain protein sequence, see Genbank accession no Y144737 and SEQ ID NO: 10. Other Fc regions can be used for example from other IgG types and from IgA, IgM, IgD, or IgE antibodies. The multimerization region of VEGF can also be used. A DNA sequence encoding VEGF is shown at Genbank accession no. NM\_003376 and SEQ ID NO: 11. An amino acid sequence of VEGF is shown at Genbank accession no. CAC19513 and SEQ ID NO: 12. The multimerization region of VEGF (SEQ ID NO: 13), encoded by VEGF exon 3 (VEGF Ex3), is at about amino acid residues 75-88 of VEGF protein (SEQ ID NO: 12). Multimerization domains will cause at least 5 %, 10%, 20%, 30%, 40%, 50%, 60%, 75%, 80%, 85%, 90%, or 95% of the monomeric fusion proteins to migrate on a non-denaturing polyacrylamide gel at a rate appropriate for a multimer. Glycosylation can affect the migration of a protein in a gel. Although particular sequences are shown here, variants such as allelic variants can be used as well. Typically such variants will have at least 85 %, 90 %, 95 %, 97 %, 98 %, or 99 % identity with the disclosed sequence.

**[0042]** Multimerization can be assayed, for example, using reducing and non-reducing gels, as demonstrated herein. Multimerization can also be assayed by detection of increased binding affinity of a protein for its ligand/receptor. BiaCore™ surface plasmon resonance assays can be used in this regard. These assays detect changes in mass by measuring changes in reactive index in an aqueous layer close to a sensor chip surface. Any method known in the art can be used

to detect multimerization.

**[0043]** Linker moieties according to the present disclosure can be comprised of for example 5-100 amino acid residues, 5-75 amino acid residues, 5-50 amino acid residues, 5-25 amino acid residues, 5-20 amino acid residues, 5-15 amino acid residues, 5-10 amino acid residues, or 5-9 amino acid residues. Examples of useful linkers include: gly<sub>9</sub> (SEQ ID NO: 27), glu<sub>9</sub> (SEQ ID NO: 28), ser<sub>9</sub> (SEQ ID NO: 29), gly<sub>5</sub>cyspro<sub>2</sub>cys (SEQ ID NO: 30), (gly<sub>4</sub>ser)<sub>3</sub> (SEQ ID NO: 31), SerCysValProLeuMetArgCysGlyGlyCysCysAsn (SEQ ID NO: 32), Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn (SEQ ID NO: 13), Gly Asp Leu Ile Tyr Arg Asn Gln Lys (SEQ ID NO: 26), and Gly<sub>9</sub>ProSerCysValProLeuMetArgCysGlyGlyCysCysAsn (SEQ ID NO: 34). Other polypeptide linkers which can be used include a polyglycine of different lengths, including of 5, 7, or 30 residues. Additionally, other portions of Flt-1 can be used as a linker, for example domain 3 of Flt-1. See SEQ ID NO: 15. Linker moieties can also be made from other polymers, such as polyethylene glycol. Such linkers can have from 10 to 1000, 10-500, 10-250, 10-100, or 10-50 ethylene glycol monomer units. Suitable polymers should be of a size similar to the size occupied by the appropriate range of amino acid residues. A typical sized polymer would provide a spacing of from about 10-25 angstroms.

**[0044]** Notwithstanding the generality of the foregoing disclosure, however, the present invention relates to a fusion protein of the formula X-Y-Z, wherein: X comprises the Ig-like domain 2 of VEGF-R1 but lacks the Ig-like domains 1 and 3 of VEGF-R1, with said Ig-like domain 2 of VEGF-R1 being covalently linked to moiety Z via moiety Y; Y consists of a 5 - 25 amino acid residue polypeptide; and Z is a CH3 region of an IgG heavy chain molecule or an Fc portion of an antibody molecule.

**[0045]** Fusion proteins according to the present disclosure, including the fusion proteins of the present invention, can be made by any means known in the art. While such proteins can be made synthetically, or by linking portions which are made, recombinant production can also be used. A fused gene sequence can be produced using the standard tools of recombinant DNA. The fused gene sequence can be inserted into a vector, for example a viral or plasmid vector, for replicating the fused gene sequence. A promoter sequence which is functional in the ultimate recipient cell can be introduced upstream of the fused gene sequence. Promoters used can be constitutive, inducible or repressible. Examples of each type are well-known in the art. The vector can be introduced into a host cell or mammal by any means known in the art. Suitable vectors which can be used include adenovirus, adeno-associated virus, retrovirus, lentivirus, and plasmids. If the vector is in a viral vector and the vector has been packaged, then the virions can be used to infect cells. If naked DNA is used, then transfection or transformation procedures as are appropriate for the particular host cells can be used. Formulations of naked DNA utilizing polymers, liposomes, or nanospheres can be used for fusion gene delivery. Cells which can be transformed or transfected with recombinant constructs according to the invention may be any which are convenient to the artisan. Exemplary cell types which may be used include bacteria, yeast, insects, and mammalian cells. Among mammalian cells, cells of many tissue types may be chosen, as is convenient. Exemplary cells which may be used are fibroblasts, hepatocytes, endothelial cells, stem cells, hematopoietic cells, epithelial cells, myocytes, neuronal cells, and keratinocytes. These cells can be used to produce protein *in vitro*, or can be delivered to mammals including humans to produce the encoded proteins *in vivo*. This means of delivery is an alternative to delivering nucleic acid to a mammal, delivering viral vector to a mammal, and delivering fusion protein to a mammal.

**[0046]** Compositions of protein or nucleic acids can be in carriers, such as buffers, aqueous or lipophilic carriers, sterile or non-sterile, pyrogenic or non-pyrogenic vehicles. Non-pyrogenic vehicles are useful for injectible formulations. Formulations can be liquid or solid, for example, lyophilized. Formulations can also be administered as aerosols. Compositions may contain one or more fusion proteins or one or more nucleic acids, or both fusion proteins and nucleic acids. The fusion proteins and or nucleic acids in a composition may be homogeneous, in which case homomultimer proteins will form, or they may be heterogeneous in the composition, in which case heteromultimer proteins will form. In the case of heteromultimers, typically the X moiety will vary between fusion proteins, but the Z moiety will be the same between fusion proteins.

**[0047]** Fusion proteins can be provided to a cell or mammalian host by any means known in the art. Protein can be delivered to the cell or host. Nucleic acid can be administered to the cell or host. Transformed or transfected cells can be administered to the cell or host. In the latter case, cells of the same genetic background are desired to reduce transplantation rejection.

**[0048]** Suitable cells for delivery to mammalian host animals include any mammalian cell type from any organ, tumor, or cell line. For example, human, murine, goat, ovine, bovine, dog, cat, and porcine cells can be used. Suitable cell types for use include without limitation, fibroblasts, hepatocytes, endothelial cells, keratinocytes, hematopoietic cells, epithelial cells, myocytes, neuronal cells, and stem cells.

**[0049]** Means of delivery of fusion proteins or nucleic acids encoding fusion proteins include delivery of cells expressing the fusion proteins, delivery of the fusion proteins, and delivery of nucleic acids encoding the fusion proteins. Fusion proteins, cells, or nucleic acids can be delivered directly to the desired organ or tumor, for example by injection, catheterization, or endoscopy. They can also be delivered intravenously, intrabronchially, intra-tumorally, intrathecally, intramuscularly, intraocularly, topically, subcutaneously, transdermally or *per os*. Patients who can be effectively treated include those with wet age-related macular degeneration, proliferative diabetic retinopathy, rheumatoid arthritis, oste-

oarthritis, uveitis, asthma, and cancer. The treatments will improve symptoms and/or markers of disease and/or disease severity.

5 [0050] Nucleic acids can be delivered to mammals, and in particular to humans, in any desired vector. These include viral or non-viral vectors, including adenovirus vectors, adeno-associated virus vectors, retrovirus vectors, lentivirus vectors, and plasmid vectors. Exemplary types of viruses include HSV (herpes simplex virus), adenovirus, AAV (adeno associated virus), HIV (human immunodeficiency virus), BIV (bovine immunodeficiency virus), and MLV (murine leukemia virus). Nucleic acids can be administered in any desired format that provides sufficiently efficient delivery levels, including in virus particles, in liposomes, in nanoparticles, and complexed to polymers.

10 [0051] Combinations of protein and nucleic acid treatments can be used. For example, a fusion protein according to the present disclosure, e.g. a fusion protein according to the present invention, can be administered to a patient. If a favorable response is observed, then a nucleic acid molecule encoding the fusion protein can be administered for a long term effect. Alternatively, the protein and nucleic acid can be administered simultaneously or approximately simultaneously. In another alternative, an antibody or fusion protein for a ligand can be administered followed by or concomitantly with an antibody or fusion partner for a receptor. Another option employs a combination of nucleic acids in which one encodes an antibody and another encodes a fusion protein. Some antibodies that can be employed in combination with the Flt-1 constructs of the present disclosure, e.g. in combination with the Flt-1 constructs of the present invention, (whether in the protein or nucleic acid form) are bevacizumab and ranibizumab, both directed to VEGF. These are particularly useful for treating cancer and macular degeneration, respectively.

15 [0052] The practice of the present disclosure, including the practice of the present invention, employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, Molecular Cloning: A Laboratory Manual, Second Edition (Sambrook et al., 1989); Current Protocols In Molecular Biology (F.M. Ausubel et al., eds., 1987); Oligonucleotide Synthesis (M.J. Gait, ed., 1984); Animal Cell Culture (R.I. Freshney, ed., 1987); Methods In Enzymology (Academic Press, Inc.); Handbook Of Experimental Immunology (D.M. Wei & C.C. Blackwell, eds.); Gene Transfer Vectors For Mammalian Cells (J.M. Miller & M.P. Calos, eds., 1987); PCR: the Polymerase Chain Reaction, (Mullis et al., eds., 1994); Current Protocols In Immunology (J.E. Coligan et al., eds., 1991); Antibodies: A Laboratory Manual (E. Harlow and D. Lane eds. (1988)); and PCR 2: A Practical Approach (M.J. MacPherson, B.D. Hames and G.R. Taylor eds. (1995)).

20 [0053] A gene delivery vehicle is any molecule that can carry inserted polynucleotides into a host cell. Examples of gene delivery vehicles are liposomes, biocompatible polymers, including natural polymers and synthetic polymers; lipoproteins; polypeptides; polysaccharides; lipopolysaccharides; artificial viral envelopes; metal particles; and bacteria, viruses, such as baculovirus, adenovirus and retrovirus, bacteriophage, cosmid, plasmid, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.

25 [0054] Gene delivery, gene transfer, and the like as used herein, are terms referring to the introduction of an exogenous polynucleotide (sometimes referred to as a "transgene") into a host cell, irrespective of the method used for the introduction. Such methods include a variety of well-known techniques such as vector-mediated gene transfer (by, e.g., viral infection/transfection, or various other protein-based or lipid-based gene delivery complexes) as well as techniques facilitating the delivery of "naked" polynucleotides (such as electroporation, "gene gun" delivery and various other techniques used for the introduction of polynucleotides). The introduced polynucleotide may be stably or transiently maintained in the host cell. Stable maintenance typically requires that the introduced polynucleotide either contains an origin of replication compatible with the host cell or integrates into a replicon of the host cell such as an extrachromosomal replicon (e.g., a plasmid) or a nuclear or mitochondrial chromosome. A number of vectors are known to be capable of mediating transfer of genes to mammalian cells, as is known in the art and described herein.

30 [0055] The exogenous polynucleotide is inserted into a vector such as adenovirus, partially-deleted adenovirus, fully-deleted adenovirus, adeno-associated virus (AAV), retrovirus, lentivirus, naked plasmid, plasmid/liposome complex, etc. for delivery to the host via intravenous, intramuscular, intraportal or other route of administration. Expression vectors which can be used in the methods and compositions of the present disclosure, e.g. in the compositions of the present invention, include, for example, viral vectors. One of the most frequently used methods of administration of gene therapy, both *in vivo* and *ex vivo*, is the use of viral vectors for delivery of the gene. Many species of virus are known, and many have been studied for gene therapy purposes. The most commonly used viral vectors include those derived from adenoviruses, adeno-associated viruses (AAV) and retroviruses, including lentiviruses, such as human immunodeficiency virus (HIV).

35 [0056] Adenovirus is a non-enveloped, nuclear DNA virus with a genome of about 36 kb, which has been well-characterized through studies in classical genetics and molecular biology (Hurwitz, M.S., Adenoviruses Virology, 3rd edition, Fields et al., eds., Raven Press, New York, 1996; Hitt, M.M. et al., Adenovirus Vectors, The Development of Human Gene Therapy, Friedman, T. ed., Cold Spring Harbor Laboratory Press, New York 1999). The viral genes are classified into early (designated E1-E4) and late (designated L1-L5) transcriptional units, referring to the generation of two temporal

classes of viral proteins. The demarcation of these events is viral DNA replication. The human adenoviruses are divided into numerous serotypes (approximately 47, numbered accordingly and classified into 6 groups: A, B, C, D, E and F), based upon properties including hemagglutination of red blood cells, oncogenicity, DNA and protein amino acid compositions and homologies, and antigenic relationships.

5 **[0057]** Recombinant adenoviral vectors have several advantages for use as gene delivery vehicles, including tropism for both dividing and non-dividing cells, minimal pathogenic potential, ability to replicate to high titer for preparation of vector stocks, and the potential to carry large inserts (Berkner, K.L., *Curr. Top. Micro. Immunol.* 158:39-66, 1992; Jolly, D., *Cancer Gene Therapy* 1:51-64 1994). Adenoviral vectors with deletions of various adenoviral gene sequences, such as pseudoadenoviral vectors (PAVs) and partially-deleted adenoviral (termed "DeAd"), have been designed to take  
10 advantage of the desirable features of adenovirus which render it a suitable vehicle for delivery of nucleic acids to recipient cells.

**[0058]** In particular, pseudoadenoviral vectors (PAVs), also known as 'gutless adenovirus' or mini-adenoviral vectors, are adenoviral vectors derived from the genome of an adenovirus that contain minimal *cis*-acting nucleotide sequences required for the replication and packaging of the vector genome and which can contain one or more transgenes (See, U.S. Patent No. 5,882,877 which covers pseudoadenoviral vectors (PAV) and methods for producing PAV). PAVs have been designed to take advantage of the desirable features of adenovirus which render it a suitable vehicle for gene  
15 delivery. While adenoviral vectors can generally carry inserts of up to 8kb in size by the deletion of regions which are dispensable for viral growth, maximal carrying capacity can be achieved with the use of adenoviral vectors containing deletions of most viral coding sequences, including PAVs. See U.S. Patent No. 5,882,877 of Gregory et al.; Kochanek et al., *Proc. Natl. Acad. Sci. USA* 93:5731-5736, 1996; Parks et al., *Proc. Natl. Acad. Sci. USA* 93:13565-13570, 1996; Lieber et al., *J. Viral.* 70:8944-8960, 1996; Fisher et al., *Virology* 217:11-22, 1996; U.S. Patent No. 5,670,488; PCT  
20 Publication No. WO96/33280, published October 24, 1996; PCT Publication No. WO96/40955, published December 19, 1996; PCT Publication No. WO97/25446, published July 19, 1997; PCT Publication No. WO95/29993, published November 9, 1995; PCT Publication No. WO97/00326, published January 3, 1997; Morral et al., *Hum. Gene Ther.* 10:  
25 2709-2716, 1998. Such PAVs, which can accommodate up to about 36 kb of foreign nucleic acid, are advantageous because the carrying capacity of the vector is optimized, while the potential for host immune responses to the vector or the generation of replication-competent viruses is reduced. PAV vectors contain the 5' inverted terminal repeat (ITR) and the 3' ITR nucleotide sequences that contain the origin of replication, and the *cis*-acting nucleotide sequence required for packaging of the PAV genome, and can accommodate one or more transgenes with appropriate regulatory elements,  
30 *e.g.* promoter, enhancers, etc.

**[0059]** Other, partially deleted adenoviral vectors provide a partially-deleted adenoviral (termed "DeAd") vector in which the majority of adenoviral early genes required for virus replication are deleted from the vector and placed within a producer cell chromosome under the control of a conditional promoter. The deletable adenoviral genes that are placed in the producer cell may include E1A/E1B, E2, E4 (only ORF6 and ORF6/7 need be placed into the cell), pIX and pIVa2.  
35 E3 may also be deleted from the vector, but since it is not required for vector production, it can be omitted from the producer cell. The adenoviral late genes, normally under the control of the major late promoter (MLP), are present in the vector, but the MLP may be replaced by a conditional promoter.

**[0060]** Conditional promoters suitable for use in DeAd vectors and producer cell lines include those with the following characteristics: low basal expression in the uninduced state, such that cytotoxic or cytostatic adenovirus genes are not  
40 expressed at levels harmful to the cell; and high level expression in the induced state, such that sufficient amounts of viral proteins are produced to support vector replication and assembly. Preferred conditional promoters suitable for use in DeAd vectors and producer cell lines include the dimerizer gene control system, based on the immunosuppressive agents FK506 and rapamycin, the ecdysone gene control system and the tetracycline gene control system. Also useful in the present disclosure, including the present invention may be the GeneSwitch™ technology (Valentis, Inc., Woodlands, TX) described in Abruzzese et al., *Hum. Gene Ther.* 1999 10:1499-507. The partially deleted adenoviral expression  
45 system is further described in WO99/57296.

**[0061]** Adeno-associated virus (AAV) is a single-stranded human DNA parvovirus whose genome has a size of 4.6 kb. The AAV genome contains two major genes: the rep gene, which codes for the rep proteins (Rep 78, Rep 68, Rep 52, and Rep 40) that are involved in AAV replication, rescue, transcription and integration; and the cap gene, which  
50 codes for the cap proteins that form the AAV viral particle. AAV derives its name from its dependence on an adenovirus or other helper virus (*e.g.*, herpesvirus) to supply essential gene products that allow AAV to undergo a productive infection, *i.e.*, reproduce itself in the host cell. In the absence of helper virus, AAV integrates as a provirus into the host cell's chromosome, until it is rescued by superinfection of the host cell with a helper virus, usually adenovirus (Muzyczka, *Curr. Top. Micor. Immunol.* 158:97-127, 1992).

55 **[0062]** Interest in AAV as a gene transfer vector results from several unique features of its biology. At both ends of the AAV genome is a nucleotide sequence known as an inverted terminal repeat (ITR), which contains the *cis*-acting nucleotide sequences required for virus replication, rescue, packaging and integration. The integration function of the ITR mediated by the rep protein in trans permits the AAV genome to integrate into a cellular chromosome after infection,

in the absence of helper virus. This unique property of the virus has relevance to the use of AAV in gene transfer, as it allows for the integration of a recombinant AAV containing a gene of interest into the cellular genome. Therefore, stable genetic transformation, ideal for many of the goals of gene transfer, may be achieved by use of rAAV vectors. Furthermore, the site of integration for AAV is well-established and has been localized to chromosome 19 of humans (Kotin et al., Proc. Natl. Acad. Sci. 87:2211-2215, 1990). This predictability of integration site reduces the danger of random insertional events into the cellular genome that may activate or inactivate host genes or interrupt coding sequences, consequences that can limit the use of vectors whose integration of AAV, removal of this gene in the design of rAAV vectors may result in the altered integration patterns that have been observed with rAAV vectors (Ponnazhagan et al., Hum Gene Ther. 8: 275-284, 1997).

**[0063]** There are other advantages to the use of AAV for gene transfer. The host range of AAV is broad. Moreover, unlike retroviruses, AAV can infect both quiescent and dividing cells. In addition, AAV has not been associated with human disease, obviating many of the concerns that have been raised with retrovirus-derived gene transfer vectors.

**[0064]** Standard approaches to the generation of recombinant rAAV vectors have required the coordination of a series of intracellular events: transfection of the host cell with an rAAV vector genome containing a transgene of interest flanked by the AAV ITR sequences, transfection of the host cell by a plasmid encoding the genes for the AAV rep and cap proteins which are required in trans, and infection of the transfected cell with a helper virus to supply the non-AAV helper functions required in trans (Muzyczka, N., Curr. Top. Micor. Immunol. 158:97-129, 1992). The adenoviral (or other helper virus) proteins activate transcription of the AAV rep gene, and the rep proteins then activate transcription of the AAV cap genes. The cap proteins then utilize the ITR sequences to package the rAAV genome into an rAAV viral particle. Therefore, the efficiency of packaging is determined, in part, by the availability of adequate amounts of the structural proteins, as well as the accessibility of any cis-acting packaging sequences required in the rAAV vector genome.

**[0065]** Retrovirus vectors are a common tool for gene delivery (Miller, Nature (1992) 357:455-460). The ability of retrovirus vectors to deliver an unrearranged, single copy gene into a broad range of rodent, primate and human somatic cells makes retroviral vectors well suited for transferring genes to a cell.

**[0066]** Retroviruses are RNA viruses wherein the viral genome is RNA. When a host cell is infected with a retrovirus, the genomic RNA is reverse transcribed into a DNA intermediate which is integrated very efficiently into the chromosomal DNA of infected cells. This integrated DNA intermediate is referred to as a provirus. Transcription of the provirus and assembly into infectious virus occurs in the presence of an appropriate helper virus or in a cell line containing appropriate sequences enabling encapsidation without coincident production of a contaminating helper virus. A helper virus is not required for the production of the recombinant retrovirus if the sequences for encapsidation are provided by co-transfection with appropriate vectors.

**[0067]** The retroviral genome and the proviral DNA have three genes: the gag, the pol, and the env, which are flanked by two long terminal repeat (LTR) sequences. The gag gene encodes the internal structural (matrix, capsid, and nucleocapsid) proteins; the po1 gene encodes the RNA-directed DNA polymerase (reverse transcriptase) and the env gene encodes viral envelope glycoproteins. The 5' and 3' LTRs serve to promote transcription and polyadenylation of the virion RNAs. The LTR contains all other cis-acting sequences necessary for viral replication. Lentiviruses have additional genes including vit vpr, tat, rev, vpu, nef, and vpx (in HIV-1, HIV-2 and/or SIV). Adjacent to the 5' LTR are sequences necessary for reverse transcription of the genome (the tRNA primer binding site) and for efficient encapsidation of viral RNA into particles (the Psi site). If the sequences necessary for encapsidation (or packaging of retroviral RNA into infectious virions) are missing from the viral genome, the result is a cis defect which prevents encapsidation of genomic RNA. However, the resulting mutant is still capable of directing the synthesis of all varion proteins.

**[0068]** Lentiviruses are complex retroviruses which, in addition to the common retroviral genes gag, po1 and env, contain other genes with regulatory or structural function. The higher complexity enables the lentivirus to modulate the life cycle thereof, as in the course of latent infection. A typical lentivirus is the human immunodeficiency virus (HIV), the etiologic agent of AIDS. *In vivo*, HIV can infect terminally differentiated cells that rarely divide, such as lymphocytes and macrophages. *In vitro*, HIV can infect primary cultures of monocyte-derived macrophages (MDM) as well as HeLa-Cd4 or T lymphoid cells arrested in the cell cycle by treatment with aphidicolin or gamma irradiation. Infection of cells is dependent on the active nuclear import of HIV preintegration complexes through the nuclear pores of the target cells. That occurs by the interaction of multiple, partly redundant, molecular determinants in the complex with the nuclear import machinery of the target cell. Identified determinants include a functional nuclear localization signal (NLS) in the gag matrix (MA) protein, the karyophilic virion-associated protein, vpr, and a C-terminal phosphotyrosine residue in the gag MA protein. The use of retroviruses for gene therapy is described, for example, in United States Patent 6,013,516; and U.S. Patent 5,994,136.

**[0069]** Other methods for delivery of DNA to cells do not use viruses for delivery. For example, cationic amphiphilic compounds can be used to deliver the nucleic acid of the present disclosure, e.g. the nucleic acid of the present invention. Because compounds designed to facilitate intracellular delivery of biologically active molecules must interact with both non-polar and polar environments (in or on, for example, the plasma membrane, tissue fluids, compartments within the cell, and the biologically active molecular itself), such compounds are designed typically to contain both polar and non-

polar domains. Compounds having both such domains may be termed amphiphiles, and many lipids and synthetic lipids that have been disclosed for use in facilitating such intracellular delivery (whether for *in vitro* or *in vivo* application) meet this definition. One particularly important class of such amphiphiles is the cationic amphiphiles. In general, cationic amphiphiles have polar groups that are capable of being positively charged at or around physiological pH, and this property is understood in the art to be important in defining how the amphiphiles interact with the many types of biologically active (therapeutic) molecules including, for example, negatively charged polynucleotides such as DNA.

**[0070]** The use of compositions comprising cationic amphiphilic compounds for gene delivery is described, for example, in United States Patent 5,049,386; US 5,279,833; US 5,650,096; US 5,747,471; US 5,767,099; US 5,910,487; US 5,719,131; US 5,840,710; US 5,783,565; US 5,925,628; US 5,912,239; US 5,942,634; US 5,948,925; US 6,022,874; U.S. 5,994,317; U.S. 5,861,397; U.S. 5,952,916; U.S. 5,948,767; U.S. 5,939,401; and U.S. 5,935,936.

**[0071]** In addition, nucleic acid of the present disclosure, e.g. nucleic acid of the present invention, can be delivered using "naked DNA". Methods for delivering a non-infectious, non-integrating DNA sequence encoding a desired polypeptide or peptide operably linked to a promoter, free from association with transfection-facilitating proteins, viral particles, liposomal formulations, charged lipids and calcium phosphate precipitating agents are described in U.S. Patent 5,580,859; U.S. 5,963,622; U.S. 5,910,488.

**[0072]** Gene transfer systems that combine viral and nonviral components have also been reported. Cristiano et al., (1993) Proc. Natl. Acad. Sci. USA 90:11548; Wu et al. (1994) J. Biol. Chem. 269:11542; Wagner et al. (1992) Proc. Natl. Acad. Sci. USA 89:6099; Yoshimura et al. (1993) J. Biol. Chem. 268:2300; Curiel et al. (1991) Proc. Natl. Acad. Sci. USA 88:8850; Kupfer et al. (1994) Human Gene Ther. 5:1437; and Gottschalk et al. (1994) Gene Ther. 1:185. In most cases, adenovirus has been incorporated into the gene delivery systems to take advantage of its endosomolytic properties. The reported combinations of viral and nonviral components generally involve either covalent attachment of the adenovirus to a gene delivery complex or co-internalization of unbound adenovirus with cationic lipid: DNA complexes.

**[0073]** For delivery of DNA and protein to the eye, administration will typically be local. This has the advantage of limiting the amount of DNA that needs to be administered and limiting systemic side-effects. Many possible modes of delivery can be used, including, but not limited to: topical administration on the cornea by a gene gun; subconjunctival injection, intracameral injection, via eye drops to the cornea, injection into the anterior chamber via the temporal limbus, intrastromal injection, corneal application combined with electrical pulses, intracorneal injection, subretinal injection, intravitreal injection, and intraocular injection. Alternatively cells can be transfected or transduced *ex vivo* and delivered by intraocular implantation. See, Auricchio, Mol. Ther. 6: 490-494, 2002; Bennett, Nature Med. 2: 649-654, 1996; Borrás, Experimental Eye Research 76: 643-652, 2003; Chaum, Survey of Ophthalmology 47: 449-469, 2002; Campochiaro, Expert Opinions in Biological Therapy 2: 537-544 (2002); Lai, Gene Therapy 9. 804 813, 2002; Pleyer, Progress in Retinal and Eye Research, 22: 277-293, 2003.

**[0074]** The effects of various proposed therapeutic agents and administrations can be tested in suitable animal models for particular diseases. For example, retinopathy of prematurity can be tested in an oxygen-induced retinopathy model in the mouse as described in Smith, Investigative Ophthalmology & Visual Science, 35: 101-111, 1994. Laser-induced choroidal neovascularization in a mouse can be used as a model for human choroidal neovascularization (CNV), which occurs in diseases such as age-related macular degeneration. Tobe, American Journal of Pathology 153: 1641-1646, 1998. Other models of CNV have been developed in primates, rats, minipigs, and rabbits. Mouse models of age-related macular degeneration have been developed in genetically-deficient mice. Mice deficient in either monocyte chemoattractant protein-1 or C-C chemokine receptor-2 develop features of age-related macular degeneration. Ambati, Nature Med. 9: 1390-1397, 2003.

**[0075]** While the invention has been described with respect to specific examples including presently preferred modes of carrying out the invention, those skilled in the art will appreciate that there are numerous variations and permutations of the above described systems and techniques that fall within the scope of the appended claims.

## EXAMPLES

### Example 1

**[0076]** Two constructs were generated: the first, D2-9Gly-Fc, containing a polyglycine 9-mer (9Gly) linker and the second, D2-Fc, with the same sequence except the 9Gly linker (Fig. 1).

**[0077]** We analyzed the amino acid sequences of D2-9Gly-Fc and D2-Fc proteins using the Protein Analysis Toolbox of the sequence analysis program Mac Vector 6.5.1. (IBI, New Haven, CT). The polyglycine 9-mer linker in the D2-9Gly-Fc sequence was identified as a region with higher than average flexibility by the flexibility prediction method of Karpus and Schultz (1985) Naturwiss, 72: 212-213. No such region was detected in the D2-Fc sequence (Fig. 1).

## Example 2

**[0078]** We tested an isolated Flt-1 Ig-like domain 2 connected to the IgG1 Fc region by a flexible polyglycine 9-mer linker (D2-9Gly-Fc). The D2-9Gly-Fc fusion protein is capable of efficiently binding VEGF and of inhibiting VEGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation. See Fig. 2. In contrast, when Flt-1 Ig-like domain 2 is linked directly to the IgG1 heavy chain (Fc) to form D2-Fc, only minimal VEGF binding was observed. See Fig. 2. Both the dimerization via IgG1 Fc and the insertion of a flexible linker appear to facilitate VEGF binding to Flt 1 domain 2. The presence of dimeric forms in both D2-9Gly-Fc and D2-Fc were confirmed by the Western blot analysis. See Fig. 3.

## Example 3

**[0079]** An intravitreal injection of AAV vector ( $1 \times 10^8$  to  $1 \times 10^9$  particles in a volume of 0.0005 mL) is administered to newborn (P0) or 1 day old (P1) C57BL/6 mice. Retinal neovascularization (NV) is induced in C57BL/6 mice by exposing P7 pups and their nursing dam to hyperoxia for 5 days. The pups are returned to room air on P12 and are euthanized at P17 (time of peak NV). (Smith LEH, Weslowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan and D'Amore PA. Oxygen-Induced Retinopathy in the Mouse. Invest Opth Vis Sci. 1994;35:101-111.) Entire paraffin embedded eyes are serially cross sectioned at 5 micron intervals. The degree of NV is determined by counting the number of endothelial cell nuclei internal to the inner limiting membrane in sections taken every 100 microns.

**[0080]** Cohorts of animals treated with the AAV vectors coding for the anti-angiogenic agents are compared to cohorts treated with vectors coding for irrelevant transgenes or with vectors that do not code for a transgene. The average number of endothelial cell nuclei in each treated eye is compared to each animal's untreated fellow eye.

## Example 4

## Generation of D2-9Gly-Ex3/CH3

**[0081]** Domain 2 of Flt-1 has been shown to be essential for VEGF<sub>165</sub> binding. However, it was demonstrated that Flit-1 domain 2 alone was incapable of binding VEGF A. (Davis-Smyth et al., 1996.) VEGF A, when present as a dimer, binds to Flt-1 through acidic residues (amino acids 63-67 of the mature protein) that allows a possible mechanism for ligand-induced dimerization of receptor (Keyt et al., 1996).

**[0082]** Therefore, a dimerization of domain 2 of Flt-1 was used as a strategy to restore the binding of domain 2 of Flt-1 to VEGF A. Fusion with a fragment of IgG heavy chain can be used for dimerization of proteins (Davis-Smyth et al., 1996). Here we demonstrate that amino acids 75-88 (*i.e.*, PSCVPLMRCGGCCN; SEQ ID NO: 13) of VEGF A (SEQ ID NO: 12) increase the biological activity of sFlt-1 hybrid proteins.

**[0083]** Initially, three hybrid proteins were engineered: D2-9Gly-Fc, D2-Fc and D2-9Gly-Ex3/CH3 (Fig. 4). All three hybrid proteins contain the same Flt-1 domain D2 as D2-9Gly-Fc. No VEGF binding was observed with D2-Fc, which does not contain the polyglycine 9-mer (9Gly) linker. The third protein, D2-9Gly-Ex3/CH3, contains the polyglycine 9-mer (9Gly) linker and the multimerization domain of VEGF (aa PSCVPLMRCGGCCN; SEQ ID NO: 13; VEGF Ex3), but it also contains the CH3 region of human IgG1 heavy chain Fc (aa 371-477 of the SEQ ID NO: 10).

**[0084]** The protein D2-Fc did not show efficient inhibitory activity in the HUVEC proliferation assay (Fig. 5) and by implication did not bind to VEGF<sub>165</sub> efficiently. However, the third hybrid protein, D2-9Gly-Ex3/CH3, which comprises domain 2 of Flt-1 fused to the CH3 region via both the 9Gly linker and the dimerization region of VEGF<sub>165</sub> (Ex 3), did demonstrate inhibitory activity in a VEGF-dependent HUVECs proliferation assay (Fig. 5). This implies that this hybrid protein binds to VEGF<sub>165</sub> efficiently.

## Example 5

Using linker (Gly<sub>4</sub>Ser)<sub>3</sub> in Flt-1 D2 construct

**[0085]** The use of several polyglycine linkers has been previously described for improvement of protein features (Mouz et al., 1996; Qiu et al., 1998). For the next construct we have used another type of linker, the 15-mer (Gly-Gly-Gly-Gly-Ser)<sub>3</sub> (Huston et al., 1988). D2-(Gly<sub>4</sub>Ser)<sub>3</sub>-Fc protein was generated and it contains Flt-1 domain 2, (Gly<sub>4</sub>Ser)<sub>3</sub> linker and the Fc region of human IgG1 heavy chain.

**[0086]** D2-(Gly<sub>4</sub>Ser)<sub>3</sub> was further characterized in HUVECs proliferation assay. Biological activity of D2-(Gly<sub>4</sub>Ser)<sub>3</sub>-Fc as measured by inhibition of HUVEC proliferation was similar to that of D2-9Gly-Fc and D2-9Gly-Ex3/CH3 (Fig. 6).

**[0087]** The D2-(Gly<sub>4</sub>Ser)<sub>3</sub>-Fc construct was further characterized by Western blot and compared to D2-9Gly-Fc (Fig. 9). Both constructs are present mostly in a dimer form and the monomer forms were detected after separation of reduced samples.

Example 6

Role of 9Gly or VEGF Ex3 in Flt-1 (D2) constructs

5 **[0088]** In order to investigate the role of 9Gly linker or VEGF dimerizing sequence Ex3 on soluble receptor VEGF binding, three other constructs were generated: D2-9Gly-CH3, D2-CH3 and D2-Ex3/CH3 (Fig. 8). All three constructs were generated and like all the previous constructs were also put under control of CMV promoter. Their VEGF blocking activity was assessed in HUVECs proliferation assay (Fig. 9).

10 **[0089]** The HUVEC proliferation assay of proteins containing the CH3 region of IgG1 has shown that D2-9Gly-CH3 (without Ex3) and protein D2-Ex3/CH3 (without 9Gly linker) had similar VEGF blocking potency as compared to the parental D2-9Gly-Ex3/CH3 protein. However, protein D2-CH3 appeared to be the weakest VEGF inhibitor from all of them (Fig. 9).

15 **[0090]** The Flt-1 ELISA data of conditioned media from transfected 293 cells has shown similar Flt 1 levels for D2-9Gly-Ex3/CH3, D2-9Gly-CH3 and D2-Ex3/CH3 and D2-CH3 (70-90 ng/ml) and a little higher (~150 ng/ml) for the least active form of D2-CH3. Western blot of D2-9Gly-CH3 and D2-CH3 constructs (Fig.10) is showing a prevalence of dimer forms in non-reduced conditions.

Example 7

20 D2-9Gly-Fc binds VEGF better than all constructs

**[0091]** VEGF binding assay allows us to compare the relative VEGF binding affinities of our soluble VEGF receptors in a cell free system.

25 **[0092]** Briefly, conditioned media containing known concentrations of soluble receptor (ranging in concentrations from 0.29 - 150 pM) were serially diluted and mixed with 10 pM VEGF. The amount of unbound VEGF was then measured by ELISA. D2-9Gly-Fc binds VEGF with higher affinity at receptor concentrations from 0.001 to ~ 0.2 pM than all other constructs. D2-CH3 has the lowest affinity to bind VEGF (Fig. 11).

References

30

**[0093]**

Davis-Smyth, et al., EMBO J., 15, 1996, 4919  
 Huston, J. S., et al. (1991) Methods Enzymol. 203, 46-88  
 35 Huston, J. S., et al. (1988) Proc. Natl. Acad. Sci. USA, 85, 5879-5883.  
 Johnson, S., et al. (1991) Methods Enzymol. 203, 88-98  
 Karpus, P. A., et al. (1985) Naturwiss., 72, 212-213.  
 Keyt, B. A., et al. (1996) J. Biol. Chem. 271: 5638 - 5646.  
 Kortt, A. A., et al. (1997) Protein Engng, 10, 423-433.  
 40 Lee, Y-L., et al. (1998) Human Gene Therapy, 9, 457-465  
 Mouz N., et al. (1996) Proc. Natl Acad Sci. USA, 93, 9414-9419.  
 Nielsen, et al. (1997) Protein Eng., 10, 1  
 Qiu, H., et al. (1998) J. Biol. Chem. 273: 11173 -11176.

45

Table of sequences

SEQ ID NO	Clone Name	Length	Type
1	FLT1D29GLYFC	1077	DNA
2	FLT1D29GLYFC	358	Protein
3	FLT1D2DEL9GLYFC	1050	DNA
4	FLT1D2DEL9GLYFC	349	Protein
5	FLT1D29GLYEX3	426	DNA
6	FLT1D29GLYEX3	141	Protein
7	FLTID29GLYEX3CH3	744	DNA
8	FLT1D29GLYEX3CH3	247	Protein
9	IGg1 HEAVY	1434	DNA

55

**EP 1 804 835 B9**

(continued)

	SEQ ID NO	Clone Name	Length	Type
	10	IgG1 HEAVY	477	Protein
5	11	VEGF	648	DNA
	12	VEGF	215	Protein
	13	VEGF exon 3 (EX3)	14	Protein
	14	FLT-1	5777	DNA
	15	FLT-1	1338	Protein
10	16	KDR	5830	DNA
	17	KDR	1356	Protein
	18	D2-CH3	675	DNA
	19	D2-CH3	224	Protein
15	20	D2-EX3-CH3	717	DNA
	21	D2-EX3-CH3	238	Protein
	22	D2-9GLY-CH3	702	DNA
	23	D2-9GLY-CH3	233	Protein
	24	D2(G4S)3-FC	1095	DNA
20	25	D2(G4S)3-FC	364	Protein
	26	random linker	9	Protein
	27	linker	9	Protein
	28	linker	9	Protein
25	29	linker	9	Protein
	30	linker	9	Protein
	31	linker	7	Protein
		linker	13	Protein
		linker	9	Protein
30		linker	23	Protein

SEQUENCE LISTING

**[0094]**

35

<110> Scaria, Abraham  
Pechan, Peter  
Wadsworth, Samuel

40

<120> MULTIMERIC CONSTRUCTS

<130> 003482.00025

<150> 60/658209

45

<151> 2005-03-04

<150> 60/608887

<151> 2004-09-13

50

<160> 34

<170> FastSEQ for Windows version 4.0

<210> 1

55

<211> 1077

<212> DNA

<213> Artificial sequence

EP 1 804 835 B9

<220>

<223> Recombinant fusion protein or sequence encoding same

<400> 1

5  
 10  
 15  
 20

atggtcagct	actgggacac	cggggtcctg	ctgtgcgcg	tgctcagctg	tctgcttctc	60
acaggatctg	gtagaccctt	cgtagagatg	tacagtgaaa	tccccgaaat	tatacacatg	120
actgaaggaa	gggagctcgt	cattccctgc	cgggttacgt	cacctaacat	cactgttact	180
ttaaaaaagt	ttccacttga	cactttgac	cctgatggaa	aacgcataat	ctgggacagt	240
agaaagggct	tcatcatac	aatgcaacg	tacaaagaaa	tagggcttct	gacctgtgaa	300
gcaacagtca	atgggcattt	gtataagaca	aactatctca	cacatcgaca	aaccggtgga	360
ggtggaggtg	gaggtggagg	tcctaaatct	tgtgacaaaa	ctcacacatg	cccaccgtgc	420
ccagcacctg	aactcctggg	gggaccgtca	gtcttcctct	tcccccaaaa	acccaaggac	480
accctcatga	tctccccggac	ccctgaggtc	acatgctggt	tggtggacgt	gagccacgaa	540
gaccctgagg	tcaagttcaa	ctggtacgtg	gacggcgtgg	aggtgcataa	tgccaagaca	600
aagccgcggg	aggagcagta	caacagcacg	taccgtgtgg	tcagcgtcct	caccgtcctg	660
caccaggact	ggctgaatgg	caaggagtac	aagtgcaagg	tctccaacaa	agccctccca	720
gccccatcg	agaaaacat	ctccaaagcc	aaagggcagc	cccgagaacc	acaggtgtac	780
accctgcccc	catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	840
aaaggcttct	atcccagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagaac	900
aactacaaga	ccacgcctcc	cgtgctggac	tccgacggct	ccttcttctc	ctacagcaag	960
ctcaccgtgg	acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	1020
gaggctctgc	acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaataag	1077

<210> 2

<211> 358

25 <212> PRT

<213> Artificial Sequence

<220>

<223> Recombinant fusion protein or sequence encoding same

30

<400> 2

35

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser  
 1 5 10 15

40

45

50

55

EP 1 804 835 B9

Cys Leu Leu Leu Thr Gly Ser Gly Arg Pro Phe Val Glu Met Tyr Ser  
 20 25 30  
 Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile  
 35 40 45  
 5 Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe  
 50 55 60  
 Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser  
 65 70 75 80  
 Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu  
 85 90 95  
 10 Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr  
 100 105 110  
 Leu Thr His Arg Gln Thr Gly Gly Gly Gly Gly Gly Gly Pro  
 115 120 125  
 Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu  
 130 135 140  
 15 Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp  
 145 150 155 160  
 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp  
 165 170 175  
 Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly  
 180 185 190  
 20 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn  
 195 200 205  
 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp  
 210 215 220  
 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro  
 225 230 235 240  
 25 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu  
 245 250 255  
 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn  
 260 265 270  
 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile  
 275 280 285  
 30 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Tyr Lys Thr  
 290 295 300  
 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys  
 305 310 315 320  
 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys  
 325 330 335  
 35 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu  
 340 345 350  
 Ser Leu Ser Pro Gly Lys  
 355

40 <210> 3  
 <211> 1050  
 <212> DNA  
 <213> Artificial sequence

45 <220>  
 <223> Recombinant fusion protein or sequence encoding same

<400> 3

50 atggtcagct actgggacac cggggctcctg ctgtgcgcgc tgctcagctg tctgcttctc 60  
 acaggatctg gtagaccttt cgtagagatg tacagtgaat tccccgaaat tatacacatg 120  
 actgaaggaa gggagctcgt cattccctgc cgggttacgt cacctaacat cactgttact 180  
 ttaaaaaagt ttccacttga cactttgatc cctgatggaa aacgcataat ctgggacagt 240  
 agaaagggtc tcatcatatc aaatgcaacg tacaaagaaa tagggcttct gacctgtgaa 300  
 55 gcaacagtca atgggcattt gtataagaca aactatctca cacatcgaca aaccctaaa 360  
 tcttgtgaca aaactcacac atgcccaccg tgcccagcac ctgaactcct ggggggaccg 420  
 tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gaccctgag 480

EP 1 804 835 B9

	gtcacatgcg	tggtggtggà	cgtgagccac	gaagaccctg	aggccaagtt	caactggtac	540
	gtggacggcg	tggaggtgca	taatgccaag	acaaagccgc	gggaggagca	gtacaacagc	600
5	acgtaccgtg	tggtcagcgt	cctcaccgtc	ctgcaccagg	actggctgaa	tggaaggag	660
	tacaagtgca	aggctctcaa	caaagccctc	ccagcccca	tcgagaaaac	catctccaaa	720
	gccaaagggc	agccccgaga	accacaggtg	tacaccctgc	ccccatcccg	ggatgagctg	780
	accaagaacc	aggtcagcct	gacctgcctg	gtcaaaggct	tctatcccag	cgacatcgcc	840
	gtggagtggg	agagcaatgg	gcagccggag	aacaactaca	agaccacgcc	tcccgtgctg	900
	gactccgacg	gctccttctt	cctctacagc	aagctcaccg	tggacaagag	caggtggcag	960
10	caggggaacg	tcttctcatg	ctccgtgatg	catgaggctc	tgcacaacca	ctacacgcag	1020
	aagagcctct	ccctgtctcc	gggtaaatag				1050

<210> 4

<211> 349

15 <212> PRT

<213> Artificial Sequence

<220>

20 <223> Recombinant fusion protein or sequence encoding same

<400> 4

25

30

35

40

45

50

55

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser  
 1 5 10  
 Cys Leu Leu Leu Thr Gly Ser Gly Arg Pro Phe Val Glu Met Tyr Ser  
 20 25 30  
 5 Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile  
 35 40 45  
 Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Lys Lys Phe  
 50 55 60  
 10 Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser  
 65 70 75 80  
 Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu  
 85 90 95  
 Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr  
 100 105 110  
 Leu Thr His Arg Gln Thr Pro Lys Ser Cys Asp Lys Thr His Thr Cys  
 115 120 125  
 15 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu  
 130 135 140  
 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu  
 145 150 155 160  
 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys  
 165 170 175  
 20 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys  
 180 185 190  
 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu  
 195 200 205  
 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys  
 210 215 220  
 25 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys  
 225 230 235 240  
 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser  
 245 250 255  
 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys  
 260 265 270  
 30 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln  
 275 280 285  
 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly  
 290 295 300  
 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln  
 305 310 315 320  
 35 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn  
 325 330 335

40 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
 340 345

&lt;210&gt; 5

45 &lt;211&gt; 426

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

50 &lt;223&gt; Recombinant fusion protein or sequence encoding same

&lt;400&gt; 5

55

EP 1 804 835 B9

```

atggtcagct actgggacac cggggtcctg ctgtgcgcgc tgctcagctg tctgcttctc      60
acaggatctg gtagaccttt cgtagagatg tacagtgaaa tccccgaaat tatacacatg      120
actgaaggaa gggagctcgt cattccctgc cgggttacgt cacctaacat cactgttact      180
ttaaanaaagt ttccacttga cactttgatc cctgatggaa aacgcataat ctgggacagt      240
5 agaaagggct tcatcataatc aaatgcaacg tacaaagaaa tagggcttct gacctgtgaa      300
gcaacagtca atgggcattt gtataagaca aactatctca cacatcgaca aaccgggtgga      360
ggtggaggtg gaggtggagg tccttcctgt gtgcccctga tgcgatgcgg gggctgctgc      420
aattag
    
```

10 <210> 6  
 <211> 141  
 <212> PRT  
 <213> Artificial Sequence

15 <220>  
 <223> Recombinant fusion protein or sequence encoding same

<400> 6

```

20 Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
   1      5      10      15
Cys Leu Leu Leu Thr Gly Ser Gly Arg Pro Phe Val Glu Met Tyr Ser
   20      25      30
Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile
   35      40      45
25 Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe
   50      55      60
Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser
   65      70      75
Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu
   80      85      90
30 Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr
   95      100      105
Leu Thr His Arg Gln Thr Gly Gly Gly Gly Gly Gly Gly Gly Gly Pro
   110      115      120
35 Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn
   125      130      135      140
    
```

40 <210> 7  
 <211> 744  
 <212> DNA  
 <213> Artificial Sequence

<220> .  
 <223> Recombinant fusion protein or sequence encoding same

<400> 7

```

atggtcagct actgggacac cggggtcctg ctgtgcgcgc tgctcagctg tctgcttctc      60
acaggatctg gtagaccttt cgtagagatg tacagtgaaa tccccgaaat tatacacatg      120
    
```

50

55

EP 1 804 835 B9

```

actgaaggaa gggagctcgt cattccctgc cgggttacgt cacctaacat cactgttact 180
ttaaaaaagt ttccacttga cactttgatc cctgatggaa aacgcataat ctgggacagt 240
agaaaaggct tcatcatac aaatgcaacg tacaaaagaaa tagggcttct gacctgtgaa 300
gcaacagtca atgggcattt gtataagaca aactatctca cacatcgaca aaccggtgga 360
5 ggtggaggtg gaggtggagg tccttcctgt gtgccctga tgcgatgcgg gggctgctgc 420
aatcagccc gagaaccaca ggtgtacacc ctgccccat cccgggatga gctgaccaag 480
aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag 540
tgggagagca atgggcagcc ggagaacaac tacaagacca cgctcccgt gctggactcc 600
gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg 660
10 aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac gcagaagagc 720
ctctccctgt ctccgggtaa atag 744

```

<210> 8  
 <211> 247  
 15 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Recombinant fusion protein or sequence encoding same  
 20  
 <400> 8

```

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
1 5 10 15
25 Cys Leu Leu Leu Thr Gly Ser Gly Arg Pro Phe Val Glu Met Tyr Ser
20 25 30
Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile
35 35 40 45
Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe
50 55 60
30 Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser
65 70 75 80
Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu
85 90 95
Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr
100 105 110
35 Leu Thr His Arg Gln Thr Gly Gly Gly Gly Gly Gly Gly Pro
115 120 125
Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn Gln Pro Arg
130 135 140
40 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys
145 150 155 160
Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
165 170 175
Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys
180 185 190
45 Thr Thr Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
195 200 205
Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
210 215 220
Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser
225 230 235 240
50 Leu Ser Leu Ser Pro Gly Lys
245

```

<210> 9  
 <211> 1434  
 <212> DNA  
 55 <213> Homo sapiens

<400> 9

atggagtttg ggctgagctg ggttttcctc gttgctcttt taagaggtgt ccagtgtcag 60  
 gtgcagctgg tggagtctgg gggaggcgtg gtccagcctg ggaggtcctt gagactctcc 120

5  
 10  
 15  
 20  
 25

tgtgcagcgt	ctggattcac	cttcagtaat	tatggcatgc	actgggtccg	ccaggctcca	180
ggcaaggggc	tggagtgggt	ggcagctata	tggtatgatg	gaagtaataa	atactatgca	240
gactccgtga	agggccgatt	caccatctcc	agagacaatt	ccaagaacac	gttgatatatg	300
caaatgaaca	gcctgagagc	cgaggacacg	gctgtgtatt	attgtgcgag	agagggtcgg	360
tgggtacgat	atactacggt	gactactatc	ggatactact	ttgactactg	gggccaggga	420
accctggfca	ccgtctcctc	agcctccacc	aagggcccat	cggtcttccc	cctggcacc	480
tcctccaaga	gcacctctgg	ggcacagcg	gccctgggct	gcctgggtcaa	ggactacttc	540
cccgaaccgg	tgacgggtgtc	gtggaactca	ggcgccctga	ccagcggcgt	gcacaccttc	600
ccggctgtcc	tacagtctc	aggactctac	tccctcagca	gcgtgggtgac	cgtgccctcc	660
agcagcttgg	gcaccagac	ctacatctgc	aacgtgaatc	acaagcccag	caacaccaag	720
gtggacaaga	gagttgagcc	caaatcttgt	gacaaaactc	acacatgccc	accgtgccca	780
gcacctgaac	tcctgggggg	accgtcagtc	ttcctcttcc	ccccaaaacc	caaggacacc	840
ctcatgatct	cccggacccc	tgaggtcaca	tgcggtgggg	tggacgtgag	ccacgaagac	900
cctgaggtca	agttcaactg	gtacgtggac	ggcgtggagg	tgcataatgc	caagacaaag	960
ccgcgggagg	agcagtacaa	cagcacgtac	cgtgtgggtca	gcgtcctcac	cgtcctgcac	1020
caggactggc	tgaatggcaa	ggagtacaag	tgcaaggtct	ccaacaaagc	cctcccagcc	1080
cccacgaga	aaaccatctc	caaagccaaa	gggcagcccc	gagaaccaca	ggtgtacacc	1140
ctgccccat	cccgggagga	gatgaccaag	aaccagggtca	gcctgaectg	cctgggtcaaa	1200
ggcttctatc	ccagcgacat	cgccgtggag	tgggagagca	atgggcagcc	ggagaacaac	1260
tacaagacca	cgctcccgt	gctggactcc	gacggctcct	tcttctctta	tagcaagctc	1320
accgtggaca	agagcaggtg	gcagcagggg	aacgtcttct	catgctccgt	gatgcatgag	1380
gctctgcaca	accactacac	gcagaagagc	ctctccctgt	ccccgggtaa	atga	1434

<210> 10

<211> 477

<212> PRT

30 <213> Homo sapiens

<400> 10

35

40

45

50

55

EP 1 804 835 B9

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly  
 1 Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln  
 5 Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe  
 Ser Asn Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu  
 10 Glu Trp Val Ala Ala Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala  
 Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn  
 Thr Leu Tyr Met Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val  
 Tyr Tyr Cys Ala Arg Glu Gly Arg Trp Val Arg Tyr Thr Thr Val Thr  
 15 Thr Ile Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr  
 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro  
 Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val  
 20 Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala  
 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly  
 Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Leu Gly  
 25 Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys  
 Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys  
 Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu  
 30

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu  
 35 Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys  
 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys  
 40 Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu  
 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys  
 Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys  
 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser  
 45 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys  
 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln  
 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Val Leu Asp Ser Asp Gly  
 50 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln  
 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn  
 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
 55

<210> 11  
 <211> 648

EP 1 804 835 B9

<212> DNA  
<213> Homo sapiens

<400> 11

5

10

15

```

atgaactttc tgctgtcttg ggtgcattgg agccttgcct tgctgctcta cctccaccat      60
gccaaagtgg cccaggctgc acccatggca gaaggaggag ggcagaatca tcacgaagtg      120
gtgaagttca tggatgtcta tcagcgcagc tactgccatc caatcgagac cctggtggac      180
atcttccagg agtaccctga tgagatcgag tacatcttca agccatcctg tgtgcccctg      240
atgcgatgcg ggggctgctg caatgacgag ggcctggagt gtgtgcccac tgaggagtcc      300
aacatcacca tgcagattat gcggatcaaa cctcaccaag gccagcacat aggagagatg      360
agcttcctac agcacaacaa atgtgaatgc agaccaaaga aagatagagc aagacaagaa      420
aaaaaatcag ttcgaggaaa gggaaagggg caaaaacgaa agcgcaagaa atcccgggat      480
aagtcctgga gcgttcctg tgggccttgc tcagagcgga gaaagcattt gtttgtacaa      540
gatccgcaga cgtgtaaatt ttcctgcaaa aacacagact cgcgttgcaa ggcgaggcag      600
cttgagttaa acgaacgtac ttgcagatgt gacaagccga ggcggtga      648
    
```

<210> 12  
<211> 215  
<212> PRT  
<213> Homo sapiens

20

<400> 12

25

30

35

```

Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu
  1      5      10      15
Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
  20      25      30
Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln
  35      40      45
Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu
  50      55      60
Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu
  65      70      75      80
Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
  85      90      95
    
```

40

45

50

```

Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His
 100      105
Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys
 115      120      125
Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys Ser Val
 130      135      140
Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys Lys Ser Arg Tyr
 145      150      155      160
Lys Ser Trp Ser Val Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys His
 165      170      175
Leu Phe Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn Thr
 180      185      190
Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr Cys
 195      200      205
Arg Cys Asp Lys Pro Arg Arg
 210      215
    
```

<210> 13  
<211> 14  
<212> PRT  
<213> Homo sapiens

55

<400> 13

Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn  
 1 5 10

5

<210> 14

<211> 5777

<212> DNA

10 <213> Homo sapiens

<400> 14

15	gcggacactc	ctctcggctc	ctccccggca	gcggcggcgg	ctcggagcgg	gctccggggc	60
	tcgggtgacg	cggccagcgg	gcctggcggc	gaggattacc	cggggaagtg	gttgtctcct	120
	ggctggagcc	gcgagacggg	cgctcagggc	gcggggccgg	cggcggcgaa	cgagaggacg	180
	gactctggcg	gccgggtcgt	tggccggggg	agcgcgggca	ccgggcgagc	aggccgcgtc	240
	gcgctcacca	tggtcagcta	ctgggacacc	ggggctctgc	tgtgcgcgct	gctcagctgt	300
	ctgcttctca	caggatctag	ttcaggttca	aaattaaag	atcctgaact	gagtttaaaa	360
	ggcaccacag	acatcatgca	agcaggccag	acactgcatc	tccaatgcag	gggggaagca	420
20	gcccataaag	ggtctttgcc	tgaaatggtg	agtaaggaaa	gcgaaaggct	gagcataact	480
	aaatctggct	gtggaagaaa	tggcaacaa	ttctgcagta	ctttaacctt	gaacacagct	540
	caagcaaacc	acactggctt	ctacagctgc	aaatatctag	ctgtacctac	ttcaaagaag	600
	aaggaaacag	aatctgcaat	ctatatatit	attagtgata	caggtagacc	tttcgtagag	660
	atgtacagtg	aaatccccga	aattatacac	atgactgaag	gaagggagct	cgtcattccc	720
	tgccgggtta	cgtcacctaa	catcactggt	actttaaaaa	agtttccact	tgacactttg	780
25	atccctgatg	gaaaacgcat	aatctgggac	agtagaaagg	gcttcatcat	atcaaatgca	840
	acgtacaaaag	aaatagggct	tctgacctgt	gaagcaacag	tcaatgggca	tttgataaag	900
	acaaactatc	tcacacatcg	acaaaccaat	acaatcatag	atgtccaaat	aagcacacca	960
	cgcccagtca	aattacttag	aggccatact	cttgtcctca	attgtactgc	taccactccc	1020
	ttgaacacga	gagttcaaat	gacctggagt	taccctgatg	aaaaaaataa	gagagcttcc	1080
	gtaagggcga	gaattgacca	aagcaattcc	catgccaaaca	tattctacag	tgttcttact	1140
30	attgacaaaa	tgcagaacaa	agacaaagga	ctttatactt	gtcgtgtaag	gagtggacca	1200
	tcattcaaat	ctgttaacac	ctcagtgcat	atatatgata	aagcattcat	cactgtgaaa	1260
	catcgaaaac	agcaggtgct	tgaaaccgta	gctggcaagc	ggtcttaccg	gctctctatg	1320
	aaagtgaagg	catttccctc	gccggaagtt	gtatgggttaa	aagatggggt	acctgcgact	1380
	gagaaatctg	ctcgctatit	gactcgtggc	tactcgttaa	ttatcaagga	cgtaactgaa	1440
	gaggatgcag	ggaattatac	aatcttgctg	agcataaaac	agtcaaatgt	gtttaaaaac	1500
35	ctcactgcca	ctctaattgt	caatgtgaaa	ccccagattt	acgaaaaggc	cgtgtcatcg	1560
	tttccagacc	cggctctcta	cccactgggc	agcagacaaa	tcctgacttg	taccgcatat	1620
	ggtatccctc	aacctacaat	caagtggttc	tggcaccctt	gtaaccataa	tcattccgaa	1680
	gcaaggtgtg	acttttgttc	caataatgaa	gagtccttta	tcctggatgc	tgacagcaac	1740
	atgggaaaca	gaattgagag	catcactcag	cgcatggcaa	taatagaagg	aaagaataag	1800
40	atggctagca	ccttggttgt	ggctgactct	agaatttctg	gaatctacat	ttgcatagct	1860

45

50

55

	tccaataaag	ttgggactgt	gggaagaaac	ataagctttt	atatacacaga	tgtgccaaat	1920
	gggtttcatg	ttaacttggg	aaaaatgccg	acggaaggag	aggacctgaa	actgtcttgc	1980
	acagtttaaca	agttcttata	cagagacggt	acttggattt	tactgcggag	agttaataac	2040
5	agaacaaatgc	actacagtat	tagcaagcaa	aaaatggcca	tcactaagga	gcactccatc	2100
	actcttaatc	ttaccatcat	gaatgtttcc	ctgcaagatt	caggcaccta	tgcttcgaga	2160
	gccaggaatg	tatacacagg	ggaagaaatc	ctccagaaga	aagaaattac	aatcagagat	2220
	caggaagcac	catacctcct	gcgaaacctc	agtgatcaca	cagtggccat	cagcagttcc	2280
	accactttag	actgtcatgc	taatggtgtc	cccgagcctc	agatcacttg	gtttaaaaac	2340
	aaccacaaaa	tacaacaaga	gccttggatt	attttaggac	caggaagcag	caactgtttt	2400
10	attgaaagag	tcacagaaga	ggatgaaggt	gtctatcact	gcaaagccac	caaccagaag	2460
	ggctctgtgg	aaagttcagc	atacctcact	gttcaaggaa	cctcggacaa	gtctaactctg	2520
	gagctgatca	ctctaacatg	cacctgtgtg	gctgcgactc	tcttctggct	cctattaacc	2580
	ctccttatcc	gaaaaatgaa	aaggtcttct	tctgaaataa	agactgacta	cctatcaatt	2640
	ataatggacc	cagatgaagt	tcctttggat	gagcagtggt	agcggctccc	ttaatgatgc	2700
	agcaagtggtg	agtttgcccg	ggagagactt	aaactgggca	aatcacttgg	aagaggggct	2760
15	tttgaaaaag	tggttcaagc	atcagcattt	ggcattaaga	aatcacctac	gtgccggact	2820
	gtggctgtga	aaatgctgaa	agagggggcc	acggccagcg	agtacaaagc	tctgatgact	2880
	gagctaaaaa	tcttgaccca	cattggccac	catctgaacg	tggttaacct	gctgggagcc	2940
	tgaccaagac	aagaggggcc	tctgatgggt	attgttgaat	actgcaaata	tggaatctc	3000
	tccaactacc	tcaagagcaa	acgtgactta	tttttctca	acaaggatgc	agcactacac	3060
	atggagccta	agaaagaaaa	aatggagcca	ggcctggaac	aaggcaagaa	accaagacta	3120
20	gatagcgtca	ccagcagcga	aagctttgcg	agctccggct	ttcaggaaga	taaaagtctg	3180
	agtgatgttg	aggaagagga	ggattctgac	ggtttctaca	aggagcccat	cactatggaa	3240
	gatctgattt	cttacagttt	tcaagtggcc	agaggcattg	agttcctgtc	ttccagaaa	3300
	tgatttatc	gggacctggc	agcgagaaac	attcttttat	ctgagaacaa	ctgggtgaag	3360
	atttgtgatt	ttggccttgc	ccgggatatt	tataagaacc	ccgattatgt	gagaaaagga	3420
	gatactcgac	ttcctctgaa	atggatggct	cccgaatcta	tctttgacaa	aatctacagc	3480
25	accaagagcg	acgtgtggct	ttacggagta	ttgctgtggg	aaatctttc	cttaggtggg	3540
	tctccatacc	caggagtaca	aatggatgag	gacttttgca	gtcgcctgag	ggaaggcatg	3600
	aggatgagag	ctcctgagta	ctctactcct	gaaatctatc	agatcatgct	ggactgctgg	3660
	cacagagacc	caaaagaaa	gccaagattt	gcagaacttg	tggaaaaact	aggtgatttg	3720
	cttcaagcaa	atgtacaaca	ggatggtaaa	gactacatcc	caatcaatgc	catactgaca	3780
	ggaaatagtg	ggtttacata	ctcaactcct	gccttctctg	aggacttctt	caaggaaagt	3840
30	atttcagctc	cgaagtttaa	ttcaggaagc	tctgatgatg	tcagatagt	aaatgctttc	3900
	aagttcatga	gcctggaaa	aatcaaaacc	tttgaagaac	ttttaccgaa	tgccactctc	3960
	atgtttgatg	actaccaggg	cgacagcagc	actctgttgg	cctctcccat	gctgaagcgc	4020
	ttcacctgga	ctgacagcaa	acccaaggcc	tcgctcaaga	ttgacttgag	agtaaccagt	4080
	aaaagtaagg	agtcggggct	gtctgatgtc	agcaggccca	gtttctgcca	ttccagctgt	4140
	gggcacgtca	gcgaaggcaa	gcgcagggtc	acctacgacc	acgctgagct	ggaaaaggaa	4200
35	atcgctgtct	gctccccgcc	cccagactac	aactcgggtg	tcctgtactc	caccccacc	4260
	atctagagtt	tgacacgaag	ccttatttct	agaagcacat	gtgtatttat	accccagga	4320
	aactagcttt	tgccagattt	atgcatatat	aagtttacac	ctttatcttt	ccatgggagc	4380
	cagctgcttt	ttgtgatttt	tttaatagtg	ctttttttt	ttgactaaca	agaatgtaac	4440
	tccagataga	gaaatagtga	caagtgaaga	acactactgc	taaactctca	tgttactcag	4500
40	tgttagagaa	atccttcta	aacccaatga	cttccctgct	ccaacccccg	ccacctcagg	4560
	gcacgcagga	ccagtttgat	tgaggagctg	cactgatcac	ccaatgcatc	acgtacccca	4620
	ctgggccagc	cctgcagccc	aaaaccaggg	gcaacaagcc	cgttagcccc	aggggatcac	4680
	tggttgccct	gagcaacatc	tccgggagtc	tctagcaggg	ctaagacatg	tgaggaggaa	4740
	aaggaaaaaa	agcaaaaagc	aagggagaaa	agagaaaacc	ggagaaggca	tgagaaaagaa	4800
	tttgagacgc	accatgtggg	cacggagggg	gacggggctc	agcaatgcca	tttcatgtgc	4860
	ttcccagctc	tgaccttct	acatttgagg	gccagccag	gagcagatgg	acagcagtg	4920
45	ggggacattt	tctggattct	gggaggcaag	aaaaggacaa	atatctttt	tggaactaaa	4980
	gcaaatttta	gacctttacc	tatggaagtg	gttctatgtc	cattctcatt	cgtggcatgt	5040
	tttgatttgt	agcactgagg	gtggcactca	actctgagcc	catacttttg	gctcctctag	5100
	taagatgcac	tgaaaactta	gccagagtta	ggttgtctcc	aggccatgat	ggccttacac	5160
	tgaaaatgtc	acattctatt	ttgggtatta	atatatagtc	cagacactta	actcaatttc	5220
	ttggatttat	tctgttttgc	acagttagtt	gtgaaagaaa	gctgagaaga	atgaaaatgc	5280
	agtcctgagg	agagttttct	ccatatcaaa	acgagggctg	atggaggaaa	aaggtcaata	5340
50	aggtcaaggg	aagaccccgt	ctctatacca	accaaacc	ttcaccaaca	cagttgggac	5400
	ccaaaacaca	ggaagtcagt	cacgtttcct	tttcatctaa	tggggattcc	actatctcac	5460
	actaatctga	aaggatgtgg	aagagcatta	gctggcgcat	attaagcact	ttaagctcct	5520
	tgagtaaaaa	ggtggtatgt	aatttatgca	aggtatttct	ccagttggga	ctcaggatat	5580
	tagttaatga	gccatcacta	gaagaaaagc	ccattttcaa	ctgctttgaa	acttgcctgg	5640

ggtctgagca tgatgggaat agggagacag ggtaggaaag ggcgctact cttcagggtc 5700  
 taaagatcaa gtgggccttg gatcgctaag ctggctctgt ttgatgctat ttatgcaagt 5760  
 tagggtctat gtattta 5777

5

<210> 15  
 <211> 1338  
 <212> PRT  
 <213> Homo sapiens

10

<220>  
 <221> DOMAIN  
 <222> (235)...(336)  
 <223> domain 3

15

<400> 15

20

25

30

35

40

45

50

55

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser  
 1 5 10 15  
 Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp Pro  
 20 25 30  
 Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala Gly Gln Thr  
 35 40 45  
 Leu His Leu Gln Cys Arg Gly Glu Ala Ala His Lys Trp Ser Leu Pro  
 50 55 60  
 Glu Met Val Ser Lys Glu Ser Glu Arg Leu Ser Ile Thr Lys Ser Ala  
 65 70 75 80  
 Cys Gly Arg Asn Gly Lys Gln Phe Cys Ser Thr Leu Thr Leu Asn Thr  
 85 90 95  
 Ala Gln Ala Asn His Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val  
 100 105 110  
 Pro Thr Ser Lys Lys Lys Glu Thr Glu Ser Ala Ile Tyr Ile Phe Ile  
 115 120 125  
 Ser Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu  
 130 135 140  
 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val  
 145 150 155 160  
 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro Leu Asp Thr  
 165 170 175  
 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser Arg Lys Gly Phe  
 180 185 190  
 Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu Leu Thr Cys Glu  
 195 200 205  
 Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr Leu Thr His Arg  
 210 215 220  
 Gln Thr Asn Thr Ile Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val  
 225 230 235 240  
 Lys Leu Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr  
 245 250 255 260  
 Pro Leu Asn Thr Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Lys  
 265 270 275  
 Asn Lys Arg Ala Ser Val Arg Arg Ile Asp Gln Ser Asn Ser His  
 280 285  
 Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys Met Gln Asn Lys  
 290 295 300  
 Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser Gly Pro Ser Phe Lys  
 305 310 315 320  
 Ser Val Asn Thr Ser Val His Ile Tyr Asp Lys Ala Phe Ile Thr Val  
 325 330 335  
 Lys His Arg Lys Gln Gln Val Leu Glu Thr Val Ala Gly Lys Arg Ser  
 340 345 350  
 Tyr Arg Leu Ser Met Lys Val Lys Ala Phe Pro Ser Pro Glu Val Val  
 355 360 365

Trp Leu Lys Asp Gly Leu Pro Ala Thr Glu Lys Ser Ala Arg Tyr Leu  
 370 375  
 Thr Arg Gly Tyr Ser Leu Ile Ile Lys Asp Val Thr Glu Glu Asp Ala  
 385 390 400  
 Gly Asn Tyr Thr Ile Leu Leu Ser Ile Lys Gln Ser Asn Val Phe Lys  
 405 410 415  
 Asn Leu Thr Ala Thr Leu Ile Val Asn Val Lys Pro Gln Ile Tyr Glu  
 420 425 430  
 Lys Ala Val Ser Ser Phe Pro Asp Pro Ala Leu Tyr Pro Glu Leu Gly Ser  
 435 440 445  
 Arg Gln Ile Leu Thr Cys Thr Ala Tyr Gly Ile Pro Gln Pro Thr Ile  
 450 455 460  
 Lys Trp Phe Trp His Pro Cys Asn His Asn His Ser Glu Ala Arg Cys  
 465 470 475 480  
 Asp Phe Cys Ser Asn Asn Glu Glu Ser Phe Ile Leu Asp Ala Asp Ser  
 485 490 495  
 Asn Met Gly Asn Arg Ile Glu Ser Ile Thr Gln Arg Met Ala Ile Ile  
 500 505 510  
 Glu Gly Lys Asn Lys Met Ala Ser Thr Leu Val Val Ala Asp Ser Arg  
 515 520 525  
 Ile Ser Gly Ile Tyr Ile Cys Ile Ala Ser Asn Lys Val Gly Thr Val  
 530 535 540  
 Gly Arg Asn Ile Ser Phe Tyr Ile Thr Asp Val Pro Asn Gly Phe His  
 545 550 555 560  
 Val Asn Leu Glu Lys Met Pro Thr Glu Gly Glu Asp Leu Lys Leu Ser  
 565 570 575 575  
 Cys Thr Val Asn Lys Phe Leu Tyr Arg Asp Val Thr Trp Ile Leu Leu  
 580 585 590  
 Arg Thr Val Asn Asn Arg Thr Met His Tyr Ser Ile Ser Lys Gln Lys  
 595 600 605  
 Met Ala Ile Thr Lys Glu His Ser Ile Thr Leu Asn Leu Thr Ile Met  
 610 615 620  
 Asn Val Ser Leu Gln Asp Ser Gly Thr Tyr Ala Cys Arg Ala Arg Asn  
 625 630 635 640  
 Val Tyr Thr Gly Glu Glu Ile Leu Gln Lys Lys Glu Ile Thr Ile Arg  
 645 650 655 655  
 Asp Gln Glu Ala Pro Tyr Leu Leu Arg Asn Leu Ser Asp His Thr Val  
 660 665 670 670  
 Ala Ile Ser Ser Ser Thr Thr Leu Asp Cys His Ala Asn Gly Val Pro  
 675 680 685 685  
 Glu Pro Gln Ile Thr Trp Phe Lys Asn Asn His Lys Ile Gln Gln Glu  
 690 695 700  
 Pro Gly Ile Ile Leu Gly Pro Gly Ser Ser Thr Leu Phe Ile Glu Arg  
 705 710 715 720  
 Val Thr Glu Glu Asp Glu Gly Val Tyr His Cys Lys Ala Thr Asn Gln  
 725 730 735 735  
 Lys Gly Ser Val Glu Ser Ser Ala Tyr Leu Thr Val Gln Gly Thr Ser  
 740 745 750  
 Asp Lys Ser Asn Leu Glu Leu Ile Thr Leu Thr Cys Thr Cys Val Ala  
 755 760 765  
 Ala Thr Leu Phe Trp Leu Leu Leu Thr Leu Leu Ile Arg Lys Met Lys  
 770 775 780  
 Arg Ser Ser Ser Glu Ile Lys Thr Asp Tyr Leu Ser Ile Ile Met Asp  
 785 790 795 800  
 Pro Asp Glu Val Pro Leu Asp Glu Gln Cys Glu Arg Leu Pro Tyr Asp  
 805 810 815  
 Ala Ser Lys Trp Glu Phe Ala Arg Glu Arg Leu Lys Leu Gly Lys Ser  
 820 825 830  
 Leu Gly Arg Gly Ala Phe Gly Lys Val Val Gln Ala Ser Ala Phe Gly  
 835 840 845  
 Ile Lys Lys Ser Pro Thr Cys Arg Thr Val Ala Val Lys Met Leu Lys  
 850 855 860  
 Glu Gly Ala Thr Ala Ser Glu Tyr Lys Ala Leu Met Thr Glu Leu Lys

865 870 875 880  
 Ile Leu Thr His Ile Gly His His Leu Asn Val Val Asn Leu Leu Gly  
 885 890 895  
 5 Ala Cys Thr Lys Gln Gly Gly Pro Leu Met Val Ile Val Glu Tyr Cys  
 900 905 910  
 Lys Tyr Gly Asn Leu Ser Asn Tyr Leu Lys Ser Lys Arg Asp Leu Phe  
 915 920 925  
 Phe Leu Asn Lys Asp Ala Ala Leu His Met Glu Pro Lys Lys Glu Lys  
 930 935 940  
 10 Met Glu Pro Gly Leu Glu Gln Gly Lys Lys Pro Arg Leu Asp Ser Val  
 945 950 955 960  
 Thr Ser Ser Glu Ser Phe Ala Ser Ser Gly Phe Gln Glu Asp Lys Ser  
 965 970 975  
 Leu Ser Asp Val Glu Glu Glu Asp Ser Asp Gly Phe Tyr Lys Glu  
 980 985 990  
 15 Pro Ile Thr Met Glu Asp Leu Ile Ser Tyr Ser Phe Gln Val Ala Arg  
 995 1000 1005  
 Gly Met Glu Phe Leu Ser Ser Arg Lys Cys Ile His Arg Asp Leu Ala  
 1010 1015 1020  
 Ala Arg Asn Ile Leu Leu Ser Glu Asn Asn Val Val Lys Ile Cys Asp  
 1025 1030 1035 1040  
 20 Phe Gly Leu Ala Arg Asp Ile Tyr Lys Asn Pro Asp Tyr Val Arg Lys  
 1045 1050 1055  
 Gly Asp Thr Arg Leu Pro Leu Lys Trp Met Ala Pro Glu Ser Ile Phe  
 1060 1065 1070  
 Asp Lys Ile Tyr Ser Thr Lys Ser Asp Val Trp Ser Tyr Gly Val Leu  
 1075 1080 1085  
 25 Leu Trp Glu Ile Phe Ser Leu Gly Gly Ser Pro Tyr Pro Gly Val Gln  
 1090 1095 1100  
 Met Asp Glu Asp Phe Cys Ser Arg Leu Arg Glu Gly Met Arg Met Arg  
 1105 1110 1115 1120  
 Ala Pro Glu Tyr Ser Thr Pro Glu Ile Tyr Gln Ile Met Leu Asp Cys  
 1125 1130 1135  
 30 Trp His Arg Asp Pro Lys Glu Arg Pro Arg Phe Ala Glu Leu Val Glu  
 1140 1145 1150  
 Lys Leu Gly Asp Leu Leu Gln Ala Asn Val Gln Gln Asp Gly Lys Asp  
 1155 1160 1165  
 Tyr Ile Pro Ile Asn Ala Ile Leu Thr Gly Asn Ser Gly Phe Thr Tyr  
 1170 1175 1180  
 35 Ser Thr Pro Ala Phe Ser Glu Asp Phe Phe Lys Glu Ser Ile Ser Ala  
 1185 1190 1195 1200  
 Pro Lys Phe Asn Ser Gly Ser Ser Asp Asp Val Arg Tyr Val Asn Ala  
 1205 1210 1215  
 Phe Lys Phe Met Ser Leu Glu Arg Ile Lys Thr Phe Glu Glu Leu Leu  
 1220 1225 1230  
 40 Pro Asn Ala Thr Ser Met Phe Asp Tyr Gln Gly Asp Ser Ser Thr  
 1235 1240 1245  
 Leu Leu Ala Ser Pro Met Leu Lys Arg Phe Thr Trp Thr Asp Ser Lys  
 1250 1255 1260  
 Pro Lys Ala Ser Leu Lys Ile Asp Leu Arg Val Thr Ser Lys Ser Lys  
 1265 1270 1275 1280  
 45 Glu Ser Gly Leu Ser Asp Val Ser Arg Pro Ser Phe Cys His Ser Ser  
 1285 1290 1295  
 Cys Gly His Val Ser Glu Gly Lys Arg Arg Phe Thr Tyr Asp His Ala  
 1300 1305 1310  
 Glu Leu Glu Arg Lys Ile Ala Cys Cys Ser Pro Pro Pro Asp Tyr Asn  
 1315 1320 1325  
 50 Ser Val Val Leu Tyr Ser Thr Pro Pro Ile  
 1330 1335

&lt;210&gt; 16

&lt;211&gt; 5830

55 &lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 16

	actgagtc	gggacccc	gagagcgg	agtggtgt	cgctgcgt	cctctgct	60
	cgccggg	cacttgcg	ccgcagaa	tccgtctg	agcctgg	tcctctcc	120
	ccggcacc	cagacgccc	tgcagccg	ggcggcgc	cgggctcc	agccctgt	180
5	gctcaact	cctgcgct	ggggtgcc	gagttcc	tccgcgct	cttctcta	240
	caggcgct	gagaaaga	cggctccc	gttctggg	tttgcgcc	ctcgaggt	300
	aggatgc	gcaagggt	gctggccg	gccctgtg	tctgcgtg	gacccggg	360
	gcctctgt	gtttgcct	tgtttctt	gatctgcc	ggctcagc	acaaaaag	420
	atacttca	ttaaggct	tacaactc	caaattac	gcagggga	gagggact	480
	gactggct	ggccaata	tcagagtg	agtgagca	gggtggag	gactgagt	540
10	agcgatgg	tcttctgt	gacactca	attccaaa	tgatcgg	tgactctg	600
	gcctaca	gcttctac	ggaaactg	ttggcctc	tcatttat	ctatgtta	660
	gattaca	ctccattt	tgcttctg	agtgacca	atggagt	gtcattac	720
	gagaacaa	acaaaact	ggtgattc	tgtctcgg	ccatttca	tctcaact	780
	tcactttg	caagatac	agaaaaga	tttgttct	atggtaac	aatttcct	840
	gacagca	agggcttt	tattccc	tacatgat	gctatgct	catggctt	900
	tgtgaag	aaattaat	tgaaagtt	cagtctat	tgtacat	tgctgttg	960
15	gggtatag	tttatgat	ggttctga	ccgtctca	gaattgaa	atctgttg	1020
	gaaaagct	tcttaaatt	tacagca	actgaact	atgtggg	tgacttca	1080
	tggaatac	cttcttcg	gcatcagc	aagaaact	taaaccg	cctaaaaa	1140
	cagctggg	gtgagatg	gaaatttt	agcacct	ctatagat	tgtaacc	1200
	agtgacca	gattgtac	ctgtgcag	tccagtgg	tgatgacc	gaagaac	1260
20	acatttgc	gggtccat	aaaacctt	gttgcctt	gaagtggc	ggaatct	1320
	gtggaagc	cgtggggg	gcgtgtca	atccctgc	agtacctg	ttaccacc	1380
	ccagaaat	aatggtat	aaatgga	ccccttga	ccaatcac	aattaa	1440
	gggcatgt	tgacgatt	ggaagtga	gaaagaga	caggaaat	cactgtca	1500
	ctaccaat	ccatttca	ggagaagc	agccatgt	tctctctg	tgtgtatg	1560
	ccacccc	ttggtgag	atctcta	tctcctgt	attcctac	gtacggca	1620
	actcaaac	tgacatgt	ggtctatg	attcctcc	cgcatcac	ccactggt	1680
25	tgccagtt	aggaagag	cgccaacg	cccagcca	ctgtctca	gacaaacc	1740
	tacccttg	aagaatgg	aagtgtgg	gacttcc	gaggaaat	aattgagt	1800
	aataaaa	aatttgc	aattgaag	aaaaacaa	ctgtaagt	ccttgtat	1860
	caagcgg	atgtgtc	tttgtaca	tgtgaagc	tcaacaa	cgggagag	1920
	gagaggtg	tctcctcc	cgtgacc	ggctctga	ttactttg	acctgac	1980
30	cagccact	agcaggag	cgtgtctt	tggtgc	cagacaga	ctcgtttg	2040
	aacctcac	ggtacaag	tgcccac	cctctgcc	tccatgtg	agagttgc	2100
	acactg	gcaagaac	ggatact	tggaattg	atgccacc	gttctcta	2160
	agcacaat	acattttg	catggag	aagaatgc	ccttgcag	ccaaggag	2220
	tatgtctg	ttgctca	caggaag	acagaaa	attgctgt	caggcag	2280
	acagtc	agcgttgg	accacgat	acaggaac	tgagaatc	gacgaca	2340
35	attgggaa	gcatcga	ctcatgca	gcatctgg	atcccc	acagatc	2400
	tggtttaa	ataatgag	ccttgtag	gactcagg	ttgtattg	ggatggga	2460
	cggaacct	ctatccgc	agtgagga	gaggacga	gcctctac	ctgccagg	2520
	tgcaggtt	ttggctgt	aaaagtgg	gcattttc	taataga	tgcccagg	2580
	aagacga	tggaatc	tattctag	ggcacggc	tgattgcc	gttcttct	2640
	ctacttct	tcatcatc	acggaccg	aagcggcc	atggaggg	actgaaga	2700
	ggctactt	ccatcgtc	ggatccag	gaactccc	tggtgaac	ttgtgaac	2760
40	ctgcctat	atgccagc	atgggaat	cccagag	ggctgaag	aggtaagc	2820
	cttggccg	gtgccttt	ccaagtga	gaagcaga	cctttgga	tgacaaga	2880
	gcaacttg	ggacagtag	agtcaaat	ttgaaaga	gagcaaca	cagtgagc	2940
	cgagctca	tgtctga	caagatcc	attcatatt	gtcaccat	caatgtgt	3000
	aaccttct	gtgcctgt	caagccag	gggccact	tggtgatt	ggaattct	3060
45	aaatttgg	acctgtcc	ttacctga	agcaagag	atgaattt	cccctaca	3120
	accaaagg	cacgattc	tcaaggg	gactacgt	gagcaatc	tgtggatc	3180
	aaacggcg	tggaacag	caccagtag	cagagctc	ccagctct	atgtgtgg	3240
	gagaagtc	tcagtgat	agaagaag	gaagctct	aagatctg	taaggact	3300
	ctgacctg	agcatctc	ctgttac	ttccaagt	ctaagggc	ggagttct	3360
	gcatcgcg	agtgtatc	cagggacc	gcggcacg	atatcctt	atcggaga	3420
50	aacgtggt	aaatctgt	ctttggct	gcccggga	tttataaa	tccagatt	3480
	gtcagaaa	gagatgct	cctccctt	aatggatg	cccagaaa	aattttg	3540

5  
10  
15  
20  
25  
30

```

agagtgtaca caatccagag tgacgtctgg tcttttggtg ttttgctgtg ggaaatattt 3600
tccttaggtg cttctccata tcctggggta aagattgatg aagaattttg taggcgattg 3660
aaagaaggaa ctagaatgag ggcccctgat tatactacac cagaaatgta ccagaccatg 3720
ctggactgct ggcacgggga gccagtcag agaccacgt ttcagagtt ggtggaacat 3780
ttgggaaatc tcttgcaagc taatgctcag caggatggca aagactacat tgttcttccg 3840
atatcagaga ctttgagcat ggaagaggat tctggactct ctctgcctac ctcacctggt 3900
tcctgtatgg aggaggagga agtatgtgac cccaaattcc attatgacaa cacagcagga 3960
atcagtcagt atctgcagaa cagtaagcga aagagccggc ctgtgagtgt aaaaacattt 4020
gaagatatcc cgttagaaga accagaagta aaagtaatcc cagatgacaa ccagacggac 4080
agtggatgg tcttgccctc agaagagctg aaaactttgg aagacagAAC caaattatct 4140
ccatcttttg gtggaatggt gccagcaaa agcagggagt ctgtggcatc tgaaggctca 4200
aaccagacaa gcggctacca gtcccgatat cactccgatg acacagacac caccgtgtac 4260
tccagtgagg aagcagaact tttaaagctg atagagattg gagtgcaaac cggtagcaca 4320
gccagattc tccagcctga ctcggggacc acactgagct ctccctctgt ttaaaggaa 4380
gcatccacac cccaactccc ggacatcaca tgagaggtct gctcagattt tgaagtgttg 4440
ttctttccac cagcaggaag tagccgcatt tgattttcat ttcgacaaca gaaaaaggac 4500
ctcggactgc agggagccag tcttctaggc atatcctgga agaggcttgt gacccaagaa 4560
tggtctgtg tcttctcca gtgttgacct gatcctcttt tttcattcat ttaaaaagca 4620
ttatcatgcc cctgctgcgg gtctcaccat gggtttagaa caaagagctt caagcaatgg 4680
ccccatctc aaagaagtag cagtacctgg ggagctgaca cttctgtaaa actagaagat 4740
aaaccaggca acgtaagtgt tcgaggtggt gaagatggga aggatttgca gggctgagtc 4800
tatccaagag gctttgttta ggacgtgggt cccaagccaa gccttaagtg tggattcgg 4860
attgatagaa aggaagacta acgttacctt gctttggaga gtactggagc ctgcaaatgc 4920
attgtgtttg ctctggtgga ggtgggcatg gggctgttcc tgaaatgtaa agggttcaga 4980
cggggtttct ggttttagaa ggttgcgtgt tcttcgagtt gggctaaagt agagttcgtt 5040
gtgctgtttc tgactcctaa tgagagttcc ttccagaccg ttagctgtct cttgccaag 5100
ccccaggaag aaaatgatgc agctctggct ccttgctcc caggctgatc cttattcag 5160
aataccacaa agaaaggaca ttcagctcaa ggctccctgc cgtgttgaag agttctgact 5220
gcacaaacca gcttctgggt tcttctggaa tgaataccct catatctgtc ctgatgtgat 5280
atgtctgaga ctgaatgcgg gaggttcaat gtgaagctgt gtgtgggtgc aaagtttcag 5340
gaaggatttt acccttttgt tcttccccct gtccccacc cactctcacc ccgcaacca 5400
tcagtatttt agttatttgg cctctactcc agtaaacctg attgggtttg ttcactctct 5460
gaatgattat tagccagact tcaaaattat tttatagccc aaattataac atctattgta 5520
ttatttagac tttaacata tagagctatt tctactgatt ttgcccctg tctgtcctt 5580
tttttcaaaa aagaaaatgt gttttttggt tggtaccata gtgtgaaatg ctgggaacaa 5640
tgactataag acatgctatg gcacatatat ttatagtctg ttatgtaga aacaaatgta 5700
atatattaaa gccttatata taatgaactt tgtactattc acattttgta tcagtattat 5760
gtagcataac aaaggtcata atgctttcag caattgatgt cattttatta aagaacattg 5820
aaaaacttga                                     5830

```

35  
40

```

<210> 17
<211> 1356
<212> PRT
<213> Homo sapiens
<400> 17

```

45  
50  
55

```

Met Gln Ser Lys Val Leu Leu Ala Val Ala Leu Trp Leu Cys Val Glu
 1      5      10      15
Thr Arg Ala Ala Ser Val Gly Leu Pro Ser Val Ser Leu Asp Leu Pro
      20      25      30
Arg Leu Ser Ile Gln Lys Asp Ile Leu Thr Ile Lys Ala Asn Thr Thr
      35      40      45
Leu Gln Ile Thr Cys Arg Gly Gln Arg Asp Leu Asp Trp Leu Trp Pro
      50      55      60
Asn Asn Gln Ser Gly Ser Glu Gln Arg Val Glu Val Thr Glu Cys Ser
      65      70      75
Asp Gly Leu Phe Cys Lys Thr Leu Thr Ile Pro Lys Val Ile Gly Asn
      80      85      90      95
Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg Glu Thr Asp Leu Ala Ser
      100      105      110
Val Ile Tyr Val Tyr Val Gln Asp Tyr Arg Ser Pro Phe Ile Ala Ser

```

			115					120				125					
	Val	Ser	Asp	Gln	His	Gly	Val	Val	Tyr	Ile	Thr	Glu	Asn	Lys	Asn	Lys	
5	Thr	Val	Val	Ile	Pro	Cys	Leu	Gly	Ser	Ile	Ser	Asn	Leu	Asn	Val	Ser	
	145					150					155					160	
	Leu	Cys	Ala	Arg	Tyr	Pro	Glu	Lys	Arg	Phe	Val	Pro	Asp	Gly	Asn	Arg	
					165					170					175		
	Ile	Ser	Trp	Asp	Ser	Lys	Lys	Gly	Phe	Thr	Ile	Pro	Ser	Tyr	Met	Ile	
			180						185					190			
10	Ser	Tyr	Ala	Gly	Met	Val	Phe	Cys	Glu	Ala	Lys	Ile	Asn	Asp	Glu	Ser	
			195					200					205				
	Tyr	Gln	Ser	Ile	Met	Tyr	Ile	Val	Val	Val	Val	Gly	Tyr	Arg	Ile	Tyr	
		210					215					220					
	Asp	Val	Val	Leu	Ser	Pro	Ser	His	Gly	Ile	Glu	Leu	Ser	Val	Gly	Glu	
15	225					230					235				240		
	Lys	Leu	Val	Leu	Asn	Cys	Thr	Ala	Arg	Thr	Glu	Leu	Asn	Val	Gly	Ile	
				245						250					255		
	Asp	Phe	Asn	Trp	Glu	Tyr	Pro	Ser	Ser	Lys	His	Gln	His	Lys	Lys	Leu	
			260						265					270			
	Val	Asn	Arg	Asp	Leu	Lys	Thr	Gln	Ser	Gly	Ser	Glu	Met	Lys	Lys	Phe	
			275					280					285				
20	Leu	Ser	Thr	Leu	Thr	Ile	Asp	Gly	Val	Thr	Arg	Ser	Asp	Gln	Gly	Leu	
		290					295					300					
	Tyr	Thr	Cys	Ala	Ala	Ser	Ser	Gly	Leu	Met	Thr	Lys	Lys	Asn	Ser	Thr	
		305				310					315				320		
	Phe	Val	Arg	Val	His	Glu	Lys	Pro	Phe	Val	Ala	Phe	Gly	Ser	Gly	Met	
				325					330						335		
25	Glu	Ser	Leu	Val	Glu	Ala	Thr	Val	Gly	Glu	Arg	Val	Arg	Ile	Pro	Ala	
				340					345					350			
	Lys	Tyr	Leu	Gly	Tyr	Pro	Pro	Pro	Glu	Ile	Lys	Trp	Tyr	Lys	Asn	Gly	
			355					360					365				
	Ile	Pro	Leu	Glu	Ser	Asn	His	Thr	Ile	Lys	Ala	Gly	His	Val	Leu	Thr	
		370					375					380					
30	Ile	Met	Glu	Val	Ser	Glu	Arg	Asp	Thr	Gly	Asn	Tyr	Thr	Val	Ile	Leu	
		385				390					395				400		
	Thr	Asn	Pro	Ile	Ser	Lys	Glu	Lys	Gln	Ser	His	Val	Val	Ser	Leu	Val	
				405					410						415		
	Val	Tyr	Val	Pro	Gln	Ile	Gly	Glu	Lys	Ser	Leu	Ile	Ser	Pro	Val		
			420					425					430				
35	Asp	Ser	Tyr	Gln	Tyr	Gly	Thr	Thr	Gln	Thr	Leu	Thr	Cys	Thr	Val	Tyr	
			435					440					445				
	Ala	Ile	Pro	Pro	Pro	His	His	Ile	His	Trp	Tyr	Trp	Gln	Leu	Glu	Glu	
		450					455					460					
	Glu	Cys	Ala	Asn	Glu	Pro	Ser	Gln	Ala	Val	Ser	Val	Thr	Asn	Pro	Tyr	
		465			470						475				480		
40	Pro	Cys	Glu	Glu	Trp	Arg	Ser	Val	Glu	Asp	Phe	Gln	Gly	Gly	Asn	Lys	
				485					490						495		
	Ile	Glu	Val	Asn	Lys	Asn	Gln	Phe	Ala	Leu	Ile	Glu	Gly	Lys	Asn	Lys	
			500					505						510			
	Thr	Val	Ser	Thr	Leu	Val	Ile	Gln	Ala	Ala	Asn	Val	Ser	Ala	Leu	Tyr	
			515					520					525				
45	Lys	Cys	Glu	Ala	Val	Asn	Lys	Val	Gly	Arg	Gly	Glu	Arg	Val	Ile	Ser	
		530					535					540					
	Phe	His	Val	Thr	Arg	Gly	Pro	Glu	Ile	Thr	Leu	Gln	Pro	Asp	Met	Gln	
		545				550					555				560		
	Pro	Thr	Glu	Gln	Glu	Ser	Val	Ser	Leu	Trp	Cys	Thr	Ala	Asp	Arg	Ser	
				565						570				575			
50	Thr	Phe	Glu	Asn	Leu	Thr	Trp	Tyr	Lys	Leu	Gly	Pro	Gln	Pro	Leu	Pro	
				580					585					590			
	Ile	His	Val	Gly	Glu	Leu	Pro	Thr	Pro	Val	Cys	Lys	Asn	Leu	Asp	Thr	
			595					600					605				
	Leu	Trp	Lys	Leu	Asn	Ala	Thr	Met	Phe	Ser	Asn	Ser	Thr	Asn	Asp	Ile	
		610					615					620					

55

Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln Asp Gln Gly Asp Tyr  
 625 630 640  
 Val Cys Leu Ala Gln Asp Arg Lys Thr Lys Lys Arg His Cys Val Val  
 645 650 655  
 Arg Gln Leu Thr Val Leu Glu Arg Val Ala Pro Thr Ile Thr Gly Asn  
 660 665 670  
 Leu Glu Asn Gln Thr Thr Ser Ile Gly Glu Ser Ile Glu Val Ser Cys  
 675 680 685  
 Thr Ala Ser Gly Asn Pro Pro Gln Ile Met Trp Phe Lys Asp Asn  
 690 695 700  
 Glu Thr Leu Val Glu Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg  
 705 710 715 720  
 Asn Leu Thr Ile Arg Arg Val Arg Lys Glu Asp Glu Gly Leu Tyr Thr  
 725 730 735  
 Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val Glu Ala Phe Phe  
 740 745 750  
 Ile Ile Glu Gly Ala Gln Glu Lys Thr Asn Leu Glu Ile Ile Ile Leu  
 755 760 765  
 Val Gly Thr Ala Val Ile Ala Met Phe Phe Trp Leu Leu Leu Val Ile  
 770 775 780  
 Ile Leu Arg Thr Val Lys Arg Ala Asn Gly Gly Glu Leu Lys Thr Gly  
 785 790 795 800  
 Tyr Leu Ser Ile Val Met Asp Pro Asp Glu Leu Pro Leu Asp Glu His  
 805 810 815  
 Cys Glu Arg Leu Pro Tyr Asp Ala Ser Lys Trp Glu Phe Pro Arg Asp  
 820 825 830  
 Arg Leu Lys Leu Gly Lys Pro Leu Gly Arg Gly Ala Phe Gly Gln Val  
 835 840 845  
 Ile Glu Ala Asp Ala Phe Gly Ile Asp Lys Thr Ala Thr Cys Arg Thr  
 850 855 860  
 Val Ala Val Lys Met Leu Lys Glu Gly Ala Thr His Ser Glu His Arg  
 865 870 875 880  
 Ala Leu Met Ser Glu Leu Lys Ile Leu Ile His Ile Gly His His Leu  
 885 890 895  
 Asn Val Val Asn Leu Leu Gly Ala Cys Thr Lys Pro Gly Gly Pro Leu  
 900 905 910  
 Met Val Ile Val Glu Phe Cys Lys Phe Gly Asn Leu Ser Thr Tyr Leu  
 915 920 925  
 Arg Ser Lys Arg Asn Glu Phe Val Pro Tyr Lys Thr Lys Gly Ala Arg  
 930 935 940  
 Phe Arg Gln Gly Lys Asp Tyr Val Gly Ala Ile Pro Val Asp Leu Lys  
 945 950 955 960  
 Arg Arg Leu Asp Ser Ile Thr Ser Ser Gln Ser Ser Ala Ser Ser Gly  
 965 970 975  
 Phe Val Glu Glu Lys Ser Leu Ser Asp Val Glu Glu Glu Glu Ala Pro  
 980 985 990  
 Glu Asp Leu Tyr Lys Asp Phe Leu Thr Leu Glu His Leu Ile Cys Tyr  
 995 1000 1005  
 Ser Phe Gln Val Ala Lys Gly Met Glu Phe Leu Ala Ser Arg Lys Cys  
 1010 1015 1020  
 Ile His Arg Asp Leu Ala Ala Arg Asn Ile Leu Leu Ser Glu Lys Asn  
 1025 1030 1035 1040  
 Val Val Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile Tyr Lys Asp  
 1045 1050 1055  
 Pro Asp Tyr Val Arg Lys Gly Asp Ala Arg Leu Pro Leu Lys Trp Met  
 1060 1065 1070  
 Ala Pro Glu Thr Ile Phe Asp Arg Val Tyr Thr Ile Gln Ser Asp Val  
 1075 1080 1085  
 Trp Ser Phe Gly Val Leu Leu Trp Glu Ile Phe Ser Leu Gly Ala Ser  
 1090 1095 1100  
 Pro Tyr Pro Gly Val Lys Ile Asp Glu Glu Phe Cys Arg Arg Leu Lys  
 1105 1110 1115 1120  
 Glu Gly Thr Arg Met Arg Ala Pro Asp Tyr Thr Thr Pro Glu Met Tyr

5 Gln Thr Met Leu Asp Cys Trp His Gly Glu Pro Ser Gln Arg Pro Thr  
 Phe Ser Glu Leu Val Glu His Leu Gly Asn Leu Leu Gln Ala Asn Ala  
 Gln Gln Asp Gly Lys Asp Tyr Ile Val Leu Pro Ile Ser Glu Thr Leu  
 Ser Met Glu Glu Asp Ser Gly Leu Ser Leu Pro Thr Ser Pro Val Ser  
 10 Cys Met Glu Glu Glu Glu Val Cys Asp Pro Lys Phe His Tyr Asp Asn  
 Thr Ala Gly Ile Ser Gln Tyr Leu Gln Asn Ser Lys Arg Lys Ser Arg  
 Pro Val Ser Val Lys Thr Phe Glu Asp Ile Pro Leu Glu Glu Pro Glu  
 Val Lys Val Ile Pro Asp Asp Asn Gln Thr Asp Ser Gly Met Val Leu  
 15 Ala Ser Glu Glu Leu Lys Thr Leu Glu Asp Arg Thr Lys Leu Ser Pro  
 Ser Phe Gly Gly Met Val Pro Ser Lys Ser Arg Glu Ser Val Ala Ser  
 Glu Gly Ser Asn Gln Thr Ser Gly Tyr Gln Ser Gly Tyr His Ser Asp  
 Asp Thr Asp Thr Thr Val Tyr Ser Ser Glu Glu Ala Glu Leu Leu Lys  
 Leu Ile Glu Ile Gly Val Gln Thr Gly Ser Thr Ala Gln Ile Leu Gln  
 20 Pro Asp Ser Gly Thr Thr Leu Ser Ser Pro Pro Val  
 1125 1130 1135  
 1140 1145 1150  
 1155 1160 1165  
 1170 1175 1180  
 1185 1190 1195  
 1200 1205 1210 1215  
 1220 1225 1230  
 1235 1240 1245  
 1250 1255 1260  
 1265 1270 1275  
 1285 1290 1295  
 1300 1305 1310  
 1315 1320 1325  
 1330 1335 1340  
 1345 1350 1355

30 <210> 18  
 <211> 675  
 <212> DNA  
 <213> Artificial Sequence

35 <220>  
 <223> Recombinant fusion protein or sequence encoding same

<400> 18

40 atggtcagct actgggacac cggggctcctg ctgtgcgcgc tgctcagctg tctgcttctc 60  
 acaggatctg gtagaccttt cgtagagatg tacagtgaaa tccccgaaat tatacacatg 120  
 actgaaggaa gggagctcgt cattccctgc cgggttacgt cacctaacaat cactgttact 180  
 ttaaaaaagt ttccacttga cactttgatc cctgatggaa aacgcataat ctggggacagt 240  
 agaaagggct tcatcatatc aaatgcaacg tacaagaaa tagggcttct gacctgtgaa 300  
 gcaacagtca atgggcattt gtataagaca aactatctca cacatcgaca aaccagccc 360  
 cgagaaccac aggtgtacac cctgccccca tcccgggatg agctgaccaa gaaccaggtc 420  
 agcctgacct gcctgggtcaa aggcttctat cccagcgaca tcgccgtgga gtgggagagc 480  
 45 aatgggcagc cggagaacaa ctacaagacc acgcctccg tgctggactc cgacggctcc 540  
 ttcttctctt acagcaagct caccgtggac aagagcaggt ggcagcaggg gaacgtcttc 600  
 tcatgctccg tgatgcatga ggctctgcac aaccactaca cgcagaagag cctctccctg 660  
 tctccgggta aatag 675

50 <210> 19  
 <211> 224  
 <212> PRT  
 <213> Artificial Sequence

55 <220>  
 <223> Recombinant fusion protein or sequence encoding same

<400> 19

EP 1 804 835 B9

1 Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser  
 5 Cys Leu Leu Leu Thr Gly Ser Gly Arg Pro Phe Val Glu Met Tyr Ser  
 10 Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile  
 15 Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe  
 20 Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser  
 25 Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu  
 30 Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr  
 35 Leu Thr His Arg Gln Thr Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu  
 40 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys  
 45 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser  
 50 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp  
 55 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser  
 60 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala  
 65 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
 70 210 215 220

<210> 20  
 <211> 717  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Recombinant fusion protein or sequence encoding same

<400> 20

atgggtcagct	actgggacac	cggggctcctg	ctgtgcgcg	tgctcagctg	tctgcttctc	60
acaggatctg	gtagacctt	cgtagagatg	tacagtgaaa	tccccgaaat	tatacacatg	120
actgaaggaa	gggagctcgt	cattccctgc	cgggttacgt	cacctaacat	cactgttact	180
ttaaaaaagt	ttccacttga	cactttgatc	cctgatggaa	aacgcataat	ctgggacagt	240
agaaagggct	tcatcatatc	aatgcaacg	tacaaagaaa	tagggcttct	gacctgtgaa	300
gcaacagtca	atgggcattt	gtataagaca	aactatctca	cacatcgaca	aacccttcc	360
tgtgtgcccc	tgatgcatg	cgggggctgc	tgcaatcagc	cccgagaacc	acaggtgtac	420
accctgcccc	catcccggga	tgagctgacc	aagaaccagg	tcagcctgac	ctgcctggtc	480
aaaggcttct	atcccagcga	catcgccgtg	gagtgggaga	gcaatgggca	gccggagaac	540
aactacaaga	ccacgcctcc	cgtgctggac	tccgacggct	ccttcttctc	ctacagcaag	600
ctcaccgtgg	acaagagcag	gtggcagcag	gggaacgtct	tctcatgctc	cgtgatgcat	660
gaggctctgc	acaaccacta	cacgcagaag	agcctctccc	tgtctccggg	taaatag	717

<210> 21  
 <211> 238  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Recombinant fusion protein or sequence encoding same

<400> 21

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser

5  
 10  
 15  
 20  
 25  
 30

1	Cys	Leu	Leu	Leu	5	Thr	Gly	Ser	Gly	10	Arg	Pro	Phe	Val	Glu	15	Met	Tyr	Ser
			20							25						30			
	Glu	Ile	Pro	Glu	Ile	Ile	His	Met	Thr	Glu	Gly	Arg	Glu	Leu	Val	Ile			
		35						40					45						
	Pro	Cys	Arg	Val	Thr	Ser	Pro	Asn	Ile	Thr	Val	Thr	Leu	Lys	Lys	Phe			
		50					55					60							
	Pro	Leu	Asp	Thr	Leu	Ile	Pro	Asp	Gly	Lys	Arg	Ile	Ile	Trp	Asp	Ser			
		65			70					75						80			
	Arg	Lys	Gly	Phe	Ile	Ile	Ser	Asn	Ala	Thr	Tyr	Lys	Glu	Ile	Gly	Leu			
				85						90					95				
	Leu	Thr	Cys	Glu	Ala	Thr	Val	Asn	Gly	His	Leu	Tyr	Lys	Thr	Asn	Tyr			
			100						105					110					
	Leu	Thr	His	Arg	Gln	Thr	Pro	Ser	Cys	Val	Pro	Leu	Met	Arg	Cys	Gly			
			115					120					125						
	Gly	Cys	Cys	Asn	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro			
		130					135					140							
	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val			
		145				150					155					160			
	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly			
				165						170					175				
	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp			
			180						185					190					
	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp			
			195					200					205						
	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala	Leu	His			
		210					215					220							
	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys					
		225				230					235								

<210> 22  
 <211> 702  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Recombinant fusion protein or sequence encoding same

<400> 22

atggtcagct	actgggacac	cggggtcctg	ctgtgcgcgc	tgctcagctg	tctgcttctc	60
acaggatctg	gtagaccttt	cgtagagatg	tacagtgaaa	tccccgaaat	tatacacatg	120
actgaaggaa	gggagctcgt	cattccctgc	cgggttacgt	cacctaacat	cactgttact	180
45	ttaaaaaagt	ttccacttga	cactttgatc	cctgatggaa	aacgcataat	240
agaaggggct	tcatcatac	aaatgcaacg	tacaaagaaa	tagggcttct	gacctgtgaa	300
gcaacagtca	atgggcattt	gtataagaca	aactatctca	cacatcgaca	aaccgggtgga	360
ggtggagggtg	gaggtggagg	tcagccccga	gaaccacagg	tgtacaccct	gccccatcc	420
cgggatgagc	tgaccaagaa	ccaggtcagc	ctgacctgcc	tggtcaaagg	cttctatccc	480
agcgacatcg	ccgtggagtg	ggagagcaat	gggcagccgg	agaacaacta	caagaccacg	540
50	cctcccgtgc	tggactccga	cggctccttc	ttcctctaca	gcaagctcac	600
agcaggtggc	agcaggggaa	cgtcttctca	tgctccgtga	tgcatgaggc	tctgcacaac	660
cactacacgc	agaagagcct	ctccctgtct	ccgggtaaaat	ag		702

<210> 23  
 <211> 233  
 <212> PRT  
 <213> Artificial Sequence

EP 1 804 835 B9

<220>

<223> Recombinant fusion protein or sequence encoding same

<400> 23

5

10

15

20

25

30

```

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser
 1      5      10      15
Cys Leu Leu Leu Thr Gly Ser Gly Arg Pro Phe Val Glu Met Tyr Ser
 20      25      30
Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile
 35      40      45
Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe
 50      55      60
Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser
 65      70      75      80
Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu
 85      90      95
Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr
 100      105      110
Leu Thr His Arg Gln Thr Gly Gly Gly Gly Gly Gly Gly Gln
 115      120      125
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu
 130      135      140
Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 145      150      155      160
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
 165      170      175
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 180      185      190
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
 195      200      205
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
 210      215      220
Lys Ser Leu Ser Leu Ser Pro Gly Lys
 225      230

```

<210> 24

<211> 1095

<212> DNA

<213> Artificial Sequence

<220>

<223> Recombinant fusion protein or sequence encoding same

<400> 24

45

50

55

EP 1 804 835 B9

	atggtcagct	actgggacac	cggggtcctg	ctgtgcgcg	tgctcagctg	tctgcttctc	60
	acaggatctg	gtagaccttt	cgtagagatg	tacagtgaaa	tccccgaaat	tatacacatg	120
	actgaaggaa	gggagctcgt	cattccctgc	cgggttacgt	cacctaacat	cactgttact	180
	ttaaaaaagt	ttccacttga	cactttgatc	cctgatggaa	aacgcataat	ctgggacagt	240
5	agaaagggct	tcatcatatc	aaatgcaacg	tacaaagaaa	tagggcttct	gacctgtgaa	300
	gcaacagtca	atgggcattt	gtataagaca	aactatctca	cacatcgaca	aaccggtgga	360
	ggtggatcgg	gtggagggtg	atcgggtgga	ggtggatcgc	ctaagagctg	cgacaaaact	420
	cacacatgcc	caccgtgccc	agcacctgaa	ctcctggggg	gaccgtcagt	cttcctcttc	480
	ccccaaaac	ccaaggacac	cctcatgatc	tcccggaccc	ctgaggtcac	atgctgtggtg	540
	gtggacgtga	gccacgaaga	ccctgaggtc	aagttcaact	ggtacgtgga	cggcgtggag	600
10	gtgcataatg	ccaagacaaa	gccgcgggag	gagcagtaca	acagcacgta	ccgtgtggtc	660
	agcgtcctca	ccgtcctgca	ccaggactgg	ctgaatggca	aggagtacaa	gtgcaaggtc	720
	tccaacaaag	ccctcccagc	ccccatcgag	aaaaccatct	ccaaagccaa	agggcagccc	780
	cgagaaccac	aggtgtacac	cctgccccca	tcccgggatg	agctgaccaa	gaaccaggtc	840
	agcctgacct	gcctggtcaa	aggcttctat	cccagcgaca	tcgccgtgga	gtgggagagc	900
	aatgggcagc	cggagaacaa	ctacaagacc	acgcctcccg	tgctggactc	cgacggctcc	960
15	ttcttcctct	acagcaagct	caccgtggac	aagagcaggt	ggcagcaggg	gaacgtcttc	1020
	tcatgctccg	tgatgcatga	ggctctgcac	aaccactaca	cgcagaagag	cctctccctg	1080
	tctccgggta	aatag					1095

<210> 25  
 <211> 364  
 <212> PRT  
 <213> Artificial Sequence  
  
 <220>  
 <223> Recombinant fusion protein or sequence encoding same  
  
 <400> 25

30

35

40

45

50

55

Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser  
 1 5 10 15  
 Cys Leu Leu Leu Thr Gly Ser Gly Arg Pro Phe Val Glu Met Tyr Ser  
 20 25 30  
 Glu Ile Pro Glu Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile  
 35 40 45  
 Pro Cys Arg Val Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe  
 50 55 60  
 Pro Leu Asp Thr Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp Ser  
 65 70 75 80  
 Arg Lys Gly Phe Ile Ile Ser Asn Ala Thr Tyr Lys Glu Ile Gly Leu  
 85 90 95  
 Leu Thr Cys Glu Ala Thr Val Asn Gly His Leu Tyr Lys Thr Asn Tyr  
 100 105  
 Leu Thr His Arg Gln Thr Gly Gly Gly Ser Gly Gly Gly Ser  
 115 120 125  
 Gly Gly Gly Gly Ser Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro  
 130 135 140  
 Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe  
 145 150 155 160  
 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val  
 165 170 175  
 Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe  
 180 185 190  
 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro  
 195 200 205  
 Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr  
 210 215 220  
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val  
 225 230 235 240  
 Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala  
 245 250 255  
 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg  
 260 265 270  
 Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly  
 275 280 285  
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro  
 290 295 300  
 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser  
 305 310 315 320  
 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln  
 325 330 335  
 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His  
 340 345 350  
 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys  
 355 360

40 <210> 26  
 <211> 9  
 <212> PRT  
 <213> Artificial sequence  
 45 <220>  
 <223> linker of fusion protein  
 50 <400> 26

Gly Asp Leu Ile Tyr Arg Asn Gln Lys  
 1 5

55 <210> 27  
 <211> 9  
 <212> PRT  
 <213> Artificial Sequence

<220>  
<223> linker moiety for fusion proteins

<400> 27

5

Gly Gly Gly Gly Gly Gly Gly Gly Gly  
1 5

<210> 28  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> linker moiety for fusion proteins

<400> 28

20

Glu Glu Glu Glu Glu Glu Glu Glu Glu  
1 5

<210> 29  
<211> 9  
<212> PRT  
<213> Artificial sequence

<220>  
<223> linker moiety for fusion proteins

<400> 29

35

Ser Ser Ser Ser Ser Ser Ser Ser Ser  
1 5

<210> 30  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> linker moiety for fusion proteins

45

<400> 30

50

Gly Gly Gly Gly Gly Cys Pro Pro Cys  
1 5

<210> 31  
<211> 7  
<212> PRT  
<213> Artificial sequence

<220>  
<223> linker moiety for fusion proteins

<400> 31

Gly Gly Gly Gly Ser Ser Ser  
 1 5

5

<210> 32

<211> 13

<212> PRT

10 <213> Artificial Sequence

<220>

<223> linker moiety for fusion proteins

15

<400> 32

Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn  
 1 5 10

20

<210> 33

<211> 9

<212> PRT

<213> Artificial Sequence

25

<220>

<223> linker moiety for fusion proteins

<400> 33

30

Gly Asp Leu Ile Tyr Arg Asn Gln Lys  
 1 5

35

<210> 34

<211> 23

<212> PRT

<213> Artificial Sequence

40

<220>

<223> linker moiety for fusion proteins

<400> 34

45

Gly Gly Gly Gly Gly Gly Gly Gly Gly Pro Ser Cys Val Pro Leu Met  
 1 5 10 15  
 Arg Cys Gly Gly Cys Cys Asn  
 20

50

**Claims**

1. A fusion protein of the formula X-Y-Z, wherein:

55

**X comprises** the Ig-like domain 2 of VEGF-R1 but lacks the Ig-like domains 1 and 3 of VEGF-R1, with said Ig-like domain 2 of VEGF-R1 being covalently linked to moiety Z via moiety Y; and  
**Y consists** of a 5 - 25 amino acid residue polypeptide; and

## EP 1 804 835 B9

**Z** is a CH3 region of an IgG heavy chain molecule or an Fc portion of an antibody molecule.

2. The fusion protein of claim 1, wherein X is the Ig-like domain 2 of VEGF-R1 (FLT-1).

5 3. The fusion protein of claim 1, wherein the polypeptide Y is flexible.

4. The fusion protein of claim 1, wherein the polypeptide Y is selected from the group consisting of gly<sub>9</sub> (SEQ ID NO: 27), glu<sub>9</sub> (SEQ ID NO: 28), seq (SEQ ID NO: 29), gly<sub>5</sub>cyspro<sub>2</sub>cys (SEQ ID NO: 30), (gly<sub>4</sub>ser)<sub>3</sub> (SEQ ID NO: 31), SerCysValProLeuMetArgCysGlyGlyCysCysAsn (SEQ ID NO: 32), Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn (SEQ ID NO: 13), Gly-Asp-Leu-Ile-Tyr-Arg-Asn-Gln-Lys (SEQ ID NO: 26), and Gly<sub>9</sub>ProSerCysValProLeuMetArgCysGlyGlyCysCysAsn (SEQ ID NO: 34).

5. The fusion protein of claim 1, wherein Z is an IgG1 CH3 region.

15 6. The fusion protein of claim 1, wherein Z is an IgG2 CH3 region.

7. The fusion protein of claim 1, wherein the Fc is an IgG Fc.

8. The fusion protein of claim 7, wherein the IgG Fc is IgG1 Fc.

20 9. A composition comprising the fusion protein of any preceding claim which further comprises one or more pharmaceutically acceptable excipients or carriers.

10. The composition of claim 9, wherein said composition is a liquid formulation.

25 11. The composition of claim 9, wherein said composition is a lyophilized formulation.

12. A composition comprising one or more fusion proteins of any one of claims 1 - 8, wherein said composition comprises multimers of said fusion proteins.

30 13. The composition of claim 12, wherein said composition consists essentially of a single species of fusion protein which forms homomultimers.

35 14. The composition of claim 12, wherein said composition consists essentially of fusion proteins, wherein the X moiety in said fusion proteins in the composition are heterogeneous.

15. The composition of claim 12, which further comprises one or more pharmaceutically acceptable excipients or carriers.

40 16. The compositions of claim 15, wherein said composition is a liquid formulation.

17. The composition of claim 15, wherein said composition is a lyophilized formulation.

18. A method of multimerizing a polypeptide X, the method comprising:

45 linking a polypeptide X to a polypeptide Z via a polypeptide Y to form polypeptide XYZ, wherein:  
**X comprises** the Ig-like domain 2 of VEGF-R1 but lacks the Ig-like domains 1 and 3 of VEGF-R1, with said Ig-like domain 2 of VEGF-R1 being covalently linked to polypeptide Z via polypeptide Y;  
**Y consists** of a 5 - 25 amino acid residue polypeptide; and  
**Z is** a CH3 region of an IgG heavy chain molecule or an Fc portion of an antibody molecule; **whereby polypeptide XYZ multimerizes.**

50 19. The method of claim 18, wherein the step of linking comprises constructing a nucleic acid molecule which encodes each of X, Y, and Z as a single open reading frame, wherein said polypeptide XYZ is expressed from the nucleic acid construct in a host cell.

55 20. The method of claim 18, wherein X is the Ig-like domain 2 of VEGF-R1 (Flt-1).

21. A nucleic acid molecule which encodes a fusion protein according to claim 1.

## EP 1 804 835 B9

22. A nucleic acid molecule according to claim 21, wherein Z is an Fc portion of an antibody molecule.
23. The nucleic acid of claim 21 or 22, wherein X is the Ig-like domain 2 of VEGF-R1 (Flt-1).
- 5 24. The nucleic acid of claim 23, wherein the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 8, 21, and 23.
25. The nucleic acid of claim 23, wherein the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 2 and 25.
- 10 26. The fusion protein of claim 1, wherein X is the Ig-like domain 2 of VEGF-R1 (Flt1) and the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 8, 21, and 23.
- 15 27. The fusion protein of claim 1, wherein X is the Ig-like domain 2 of VEGF-R1 (Flt-1) and the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 2 and 25.
28. A mammalian cell which comprises the nucleic acid of any one of claims 21 - 25.
29. The mammalian cell of claim 28 which is a human cell.
- 20 30. The mammalian cell of claim 29 which is selected from the group consisting of a fibroblast, a hepatocyte, an endothelial cell, a keratinocyte, a hematopoietic cell, a synoviocyte, an epithelial cell, a retinal cell and a stem cell.
- 25 31. An *in vitro* method comprising:  
delivering the nucleic acid of any one of claims 21 - 25 to an isolated mammalian cell to form a cell which expresses said fusion protein.
- 30 32. The method of claim 31, wherein the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 2, 8, 21, 23, and 25.
33. The method of claim 31 or 32 further comprising:  
using the cell which expresses said fusion protein for the manufacture of a composition for delivery to a mammal.
- 35 34. The mammalian cell of any one of claims 28-30, for use in treating a mammal
35. The nucleic acid of any one of claims 21-25, for use in treating a mammal, whereby said fusion protein is expressed in the mammal.
- 40 36. The nucleic acid of claim 35 wherein the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 2, 8, 21, 23, and 25.
- 45 37. The mammalian cell of claim 34, or the nucleic acid of claim 35, wherein the mammal has wet age-related macular degeneration or proliferative diabetic retinopathy.
38. The mammalian cell of claim 34, or the nucleic acid of claim 35, wherein the mammal has cancer.
39. The mammalian cell of claim 34, or the nucleic acid of claim 35, wherein the mammal has rheumatoid arthritis.
- 50 40. The mammalian cell of claim 34, or the nucleic acid of claim 35, wherein the mammal has asthma.
41. The mammalian cell of claim 34, or the nucleic acid of claim 35, wherein the mammal has osteoarthritis.
- 55 42. The fusion protein of any one of claims 1 - 8, for use in treating a mammal.
43. The fusion protein of claim 42, wherein the mammal has wet age-related macular degeneration or proliferative diabetic retinopathy.

44. The fusion protein of claim 42, wherein the mammal has cancer.
45. The fusion protein of claim 42, wherein the mammal has rheumatoid arthritis.
- 5 46. The fusion protein of claim 42, wherein the mammal has asthma.
47. The fusion protein of claim 42, wherein the mammal has osteoarthritis.
- 10 48. The fusion protein of claim 42, wherein the the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 2, 8, 21, 23, and 25.
49. A vector which comprises the nucleic acid of any one of claims 21-25.
- 15 50. The vector of claim 49, wherein the vector is a viral vector that is selected from the group consisting of an adenovirus vector, an adeno-associated virus vector, a retrovirus vector, and a lentivirus vector.
51. The vector of claim 50, wherein the vector is an adeno-associated virus vector.
- 20 52. The vector of any one of claims 49-51, for use in treating a mammal.
53. The vector of claim 52, wherein the mammal has wet age-related macular degeneration or proliferative diabetic retinopathy.
- 25 54. The vector of claim 52, wherein the mammal has cancer.
55. The vector of claim 52, wherein the mammal has rheumatoid arthritis.
56. The vector of claim 52, wherein the mammal has asthma.
- 30 57. The vector of claim 52, wherein the mammal has osteoarthritis.

### Patentansprüche

- 35 1. Fusionsprotein der Formel X-Y-Z, wobei:
- X die Ig-ähnliche Domäne 2 von VEGF-R1 umfasst, aber nicht die Ig-ähnlichen Domänen 1 und 3 von VEGF-R1 enthält, wobei die Ig-ähnliche Domäne 2 von VEGF-R1 kovalent an die Einheit Z über die Einheit Y gebunden ist; und
- 40 Y aus einem 5 bis 25 Aminosäurerest-Polypeptid besteht; und
- Z eine CH3-Region eines IgG-Schwere-Kette-Moleküls oder ein Fc-Teil eines Antikörpermoleküls ist.
2. Fusionsprotein nach Anspruch 1, wobei X die Ig-ähnliche Domäne 2 von VEGF-R1 (FLT-1) ist.
- 45 3. Fusionsprotein nach Anspruch 1, wobei das Polypeptid Y flexibel ist.
4. Fusionsprotein nach Anspruch 1, wobei das Polypeptid Y aus der Gruppe ausgewählt ist, welche aus gly<sub>9</sub> (SEQ ID Nr.: 27), glu<sub>9</sub> (SEQ ID Nr.: 28), ser<sub>9</sub> (SEQ ID Nr.: 29), gly<sub>5</sub>scyspro<sub>2</sub>cys (SEQ ID Nr.: 30), (gly<sub>4</sub>ser)<sub>3</sub> (SEQ ID Nr.: 31), SerCysValProLeuMetArgCysGlyGlyCysCysAsn (SEQ ID Nr.: 32), Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn (SEQ ID Nr.: 13), Gly-Asp-Leu-Ile-Tyr-Arg-Asn-Gln-Lys (SEQ ID Nr.: 26) und Gly<sub>9</sub>ProSerCysValProLeuMetArgCysGlyGlyCysCysAsn (SEQ ID Nr.: 34) besteht.
- 50 5. Fusionsprotein nach Anspruch 1, wobei Z eine IgG1-CH3-Region ist.
- 55 6. Fusionsprotein nach Anspruch 1, wobei Z eine IgG2-CH3-Region ist.
7. Fusionsprotein nach Anspruch 1, wobei das Fc ein IgG-Fc ist.

## EP 1 804 835 B9

8. Fusionsprotein nach Anspruch 7, wobei das IgG-Fc IgG1-Fc ist.
9. Zusammensetzung, umfassend das Fusionsprotein nach einem vorhergehenden Anspruch, welche ferner einen oder mehrere pharmazeutisch verträgliche Exzipienten oder Träger umfasst.
- 5 10. Zusammensetzung nach Anspruch 9, wobei die Zusammensetzung eine flüssige Formulierung ist.
11. Zusammensetzung nach Anspruch 9, wobei die Zusammensetzung eine lyophilisierte Formulierung ist.
- 10 12. Zusammensetzung, umfassend ein oder mehrere Fusionsproteine nach einem der Ansprüche 1 bis 8, wobei die Zusammensetzung Multimere der Fusionsproteine umfasst.
13. Die Zusammensetzung nach Anspruch 12, wobei die Zusammensetzung im Wesentlichen aus einer einzigen Spezies von Fusionsprotein, welche Homomultimere bildet, besteht.
- 15 14. Zusammensetzung nach Anspruch 12, wobei die Zusammensetzung im Wesentlichen aus Fusionsproteinen besteht, wobei die Einheit X in den Fusionsproteinen in der Zusammensetzung heterogen ist.
15. Zusammensetzung nach Anspruch 12, welche ferner einen oder mehrere pharmazeutisch verträgliche Exzipienten oder Träger umfasst.
- 20 16. Zusammensetzung nach Anspruch 15, wobei die Zusammensetzung eine flüssige Formulierung ist.
17. Zusammensetzung nach Anspruch 15, wobei die Zusammensetzung eine lyophilisierte Formulierung ist.
- 25 18. Verfahren zur Multimerisierung eines Polypeptids X, wobei das Verfahren umfasst:
- das Binden eines Polypeptids X an ein Polypeptid Z über ein Polypeptid Y, um ein Polypeptid XYZ zu bilden, wobei:
- 30
- X die Ig-ähnliche Domäne 2 von VEGF-R1 umfasst, aber nicht die Ig-ähnlichen Domänen 1 und 3 von VEGF-R1 enthält, wobei die Ig-ähnliche Domäne 2 von VEGF-R1 kovalent an das Polypeptid Z über das Polypeptid Y gebunden ist;
- Y aus einem 5 bis 25 Aminosäurerest-Polypeptid besteht; und
- 35
- Z eine CH3-Region eines IgG-Schwere-Kette-Moleküls oder ein Fc-Teil eines Antikörpermoleküls ist;
- wobei das Polypeptid XYZ multimerisiert.
19. Verfahren nach Anspruch 18, wobei der Schritt des Bindens das Aufbauen eines Nukleinsäuremoleküls umfasst, das jedes von X, Y und Z als einen einzelnen offenen Leserahmen kodiert, wobei das Polypeptid XYZ von dem Nukleinsäurekonstrukt in einer Wirtszelle exprimiert wird.
- 40 20. Verfahren nach Anspruch 18, wobei X die Ig-ähnliche Domäne 2 von VEGF-R1 (Flt-1) ist.
- 45 21. Nukleinsäuremolekül, welches ein Fusionsprotein gemäß Anspruch 1 kodiert.
22. Nukleinsäuremolekül gemäß Anspruch 21, wobei Z ein Fc-Teil eines Antikörpermoleküls ist.
23. Nukleinsäure nach Anspruch 21 oder 22, wobei X die Ig-ähnliche Domäne 2 von VEGF-R1 (Flt-1) ist.
- 50 24. Nukleinsäure nach Anspruch 23, wobei das Fusionsprotein eine Sequenz umfasst, welche aus der Gruppe ausgewählt ist, die aus SEQ ID Nr.: 8, 21 und 23 besteht.
25. Nukleinsäure nach Anspruch 23, wobei das Fusionsprotein eine Sequenz umfasst, welche aus der Gruppe ausgewählt ist, die aus SEQ ID Nr.: 2 und 25 besteht.
- 55 26. Fusionsprotein nach Anspruch 1, wobei X die Ig-ähnliche Domäne 2 von VEGF-R1 (Flt-1) ist und das Fusionsprotein eine Sequenz umfasst, welche aus der Gruppe ausgewählt ist, die aus SEQ ID Nr.: 8, 21 und 23 besteht.

## EP 1 804 835 B9

27. Fusionsprotein nach Anspruch 1, wobei X die Ig-ähnliche Domäne 2 von VEGF-R1 (Flt-1) ist und das Fusionsprotein eine Sequenz umfasst, welche aus der Gruppe ausgewählt ist, die aus SEQ ID Nr.: 2 und 25 besteht.
- 5 28. Säugerzelle, welche die Nukleinsäure nach einem der Ansprüche 21 bis 25 umfasst.
29. Säugerzelle nach Anspruch 28, welche eine humane Zelle ist.
30. Säugerzelle nach Anspruch 29, welche aus der Gruppe ausgewählt ist, die aus einem Fibroblast, einem Hepatozyten, einer Endothelzelle, einem Keratinozyten, einer hämopoetischen Zelle, einem Synoviozyten, einer Epithelzelle, einer Retinazelle und einer Stammzelle besteht.
- 10 31. *In vitro*-Verfahren, umfassend:
- Zuführen der Nukleinsäure nach einem der Ansprüche 21 bis 25 zu einer isolierten Säugerzelle, um eine Zelle zu bilden, welche das Fusionsprotein exprimiert.
- 15 32. Verfahren nach Anspruch 31, wobei das Fusionsprotein eine Sequenz umfasst, welche aus der Gruppe ausgewählt ist, die aus SEQ ID Nr.: 2, 8, 21, 23 und 25 besteht.
- 20 33. Verfahren nach Anspruch 31 oder 32, ferner umfassend:
- das Verwenden der Zelle, welche das Fusionsprotein exprimiert, zur Herstellung einer Zusammensetzung zum Zuführen zu einem Säuger.
- 25 34. Säugerzelle nach einem der Ansprüche 28 bis 30 zur Verwendung in der Behandlung eines Säugers.
35. Nukleinsäure nach einem der Ansprüche 21 bis 25 zur Verwendung in der Behandlung eines Säugers, wobei das Fusionsprotein in dem Säuger exprimiert wird.
- 30 36. Nukleinsäure nach Anspruch 35, wobei das Fusionsprotein eine Sequenz umfasst, welche aus der Gruppe ausgewählt ist, die aus SEQ ID Nr.: 2, 8, 21, 23 und 25 besteht.
- 35 37. Säugerzelle nach Anspruch 34 oder Nukleinsäure nach Anspruch 35, wobei der Säuger eine mit dem Alter in Zusammenhang stehende feuchte Makuladegeneration oder Retinopathia diabetica haemorrhagica proliferans aufweist.
38. Säugerzelle nach Anspruch 34 oder Nukleinsäure nach Anspruch 35, wobei der Säuger Krebs hat.
39. Säugerzelle nach Anspruch 34 oder Nukleinsäure nach Anspruch 35, wobei der Säuger rheumatoide Arthritis aufweist.
- 40 40. Säugerzelle nach Anspruch 34 oder Nukleinsäure nach Anspruch 35, wobei der Säuger Asthma hat.
41. Säugerzelle nach Anspruch 34 oder Nukleinsäure nach Anspruch 35, wobei der Säuger Osteoarthritis aufweist.
- 45 42. Fusionsprotein nach einem der Ansprüche 1 bis 8 zur Verwendung in der Behandlung eines Säugers.
43. Fusionsprotein nach Anspruch 42, wobei der Säuger eine mit dem Alter in Zusammenhang stehende feuchte Makuladegeneration oder Retinopathia diabetica haemorrhagica proliferans aufweist.
- 50 44. Fusionsprotein nach Anspruch 42, wobei der Säuger Krebs hat.
45. Fusionsprotein nach Anspruch 42, wobei der Säuger rheumatoide Arthritis aufweist.
- 55 46. Fusionsprotein nach Anspruch 42, wobei der Säuger Asthma hat.
47. Fusionsprotein nach Anspruch 42, wobei der Säuger Osteoarthritis aufweist.

## EP 1 804 835 B9

48. Fusionsprotein nach Anspruch 42, wobei das Fusionsprotein eine Sequenz umfasst, welche aus der Gruppe ausgewählt ist, die aus SEQ ID Nr.: 2, 8, 21, 23 und 25 besteht.
49. Vektor, welcher die Nukleinsäure nach einem der Ansprüche 21 bis 25 umfasst.
50. Vektor nach Anspruch 49, wobei der Vektor ein viraler Vektor ist, welcher aus der Gruppe ausgewählt ist, die aus einem Adenovirusvektor, einem Adeno-assoziierten Virusvektor, einem Retrovirusvektor und einem Lentivirusvektor besteht.
51. Vektor nach Anspruch 50, wobei der Vektor ein Adeno-assoziiertes Virusvektor ist.
52. Vektor nach einem der Ansprüche 49 bis 51 zur Verwendung in der Behandlung eines Säugers.
53. Vektor nach Anspruch 52, wobei der Säuger eine mit dem Alter in Zusammenhang stehende feuchte Makuladegeneration oder Retinopathia diabetica haemorrhagica proliferans aufweist.
54. Vektor nach Anspruch 52, wobei der Säuger Krebs hat.
55. Vektor nach Anspruch 52, wobei der Säuger rheumatoide Arthritis aufweist.
56. Vektor nach Anspruch 52, wobei der Säuger Asthma hat.
57. Der Vektor nach Anspruch 52, wobei der Säuger Osteoarthritis aufweist.

### Revendications

1. Protéine de fusion de formule X-Y-Z, dans laquelle :
- X comprend le domaine 2 de type Ig du VEGF-R1 mais ne possède pas les domaines 1 et 3 de type Ig du VEGF-R1, avec ledit domaine 2 de type Ig du VEGF-R1 étant lié de manière covalente à la fraction Z via la fraction Y ;  
et  
Y est constitué par un polypeptide de 5 à 25 résidus d'acides aminés ; et  
Z est une région CH3 d'une molécule de chaîne lourde d'IgG ou une partie Fc d'une molécule d'anticorps.
2. Protéine de fusion selon la revendication 1, dans laquelle X est le domaine 2 de type Ig du VEGF-R1 (FLT-1).
3. Protéine de fusion selon la revendication 1, dans laquelle le polypeptide Y est flexible.
4. Protéine de fusion selon la revendication 1, dans laquelle le polypeptide Y est choisi dans le groupe constitué par gly<sub>9</sub> (SEQ ID NO : 27), glu<sub>9</sub> (SEQ ID NO : 28), ser<sub>9</sub> (SEQ ID NO : 29), gly<sub>5</sub>cyspro<sub>2</sub>cys (SEQ ID NO : 30), (gly<sub>4</sub>ser)<sub>3</sub> (SEQ ID NO : 31), SerCysValProLeuMetArgCysGlyGlyCysCysAsn (SEQ ID NO : 32), Pro Ser Cys Val Pro Leu Met Arg Cys Gly Gly Cys Cys Asn (SEQ ID NO : 13), Gly-Asp-Leu-Ile-Tyr-Arg-Asn-Gln-Lys (SEQ ID NO : 26), et Gly<sub>9</sub>ProSerCysValProLeuMetArgCysGlyGlyCysCysAsn (SEQ ID NO : 34).
5. Protéine de fusion selon la revendication 1, dans laquelle Z est une région CH3 d'une IgG1.
6. Protéine de fusion selon la revendication 1, dans laquelle Z est une région CH3 d'une IgG2.
7. Protéine de fusion selon la revendication 1, dans laquelle le Fc est un Fc d'une IgG.
8. Protéine de fusion selon la revendication 7, dans laquelle le Fc de l'IgG est un Fc d'IgG1.
9. Composition comprenant la protéine de fusion selon l'une quelconque des revendications précédentes, qui comprend en outre un ou plusieurs excipients ou vecteurs pharmaceutiquement acceptables.
10. Composition selon la revendication 9, ladite composition étant une formulation liquide.

## EP 1 804 835 B9

11. Composition selon la revendication 9, ladite composition étant une formulation lyophilisée.
12. Composition comprenant une ou plusieurs protéines de fusion selon l'une quelconque des revendications 1 à 8, ladite composition comprenant des multimères desdites protéines de fusion.
- 5 13. Composition selon la revendication 12, ladite composition étant essentiellement constituée par une espèce unique de protéine de fusion qui forme des homomultimères.
- 10 14. Composition selon la revendication 12, ladite composition étant essentiellement constituée par des protéines de fusion, la fraction X dans lesdites protéines de fusion dans la composition étant hétérogène.
- 15 15. Composition selon la revendication 12, qui comprend en outre un ou plusieurs excipients ou vecteurs pharmaceutiquement acceptables.
16. Composition selon la revendication 15, ladite composition étant une formulation liquide.
17. Composition selon la revendication 15, ladite composition étant une formulation lyophilisée.
- 20 18. Procédé de multimérisation d'un polypeptide X, le procédé comprenant :
- la liaison d'un polypeptide X à un polypeptide Z via un polypeptide Y pour former un polypeptide XYZ, dans lequel :
- X comprend le domaine 2 de type Ig du VEGF-R1 mais ne possède pas les domaines 1 et 3 de type Ig du VEGF-R1, avec ledit domaine 2 de type Ig du VEGF-R1 étant lié de manière covalente à la fraction Z via la fraction Y ;
- 25 Y est constitué par un polypeptide de 5 à 25 résidus d'acides aminés ; et
- Z est une région CH3 d'une molécule de chaîne lourde d'IgG ou une partie Fc d'une molécule d'anticorps,
- moyennant quoi le polypeptide XYZ se multimérise.
- 30 19. Procédé selon la revendication 18, dans lequel l'étape de liaison comprend la construction d'une molécule d'acide nucléique qui code pour chacun de X, Y et Z comme un cadre de lecture ouvert unique, ledit polypeptide XYZ étant exprimé par la construction d'acide nucléique dans une cellule hôte.
- 35 20. Procédé selon la revendication 18, dans lequel X est le domaine 2 de type Ig du VEGF-1 (Flt-1).
21. Molécule d'acide nucléique qui code pour une protéine de fusion selon la revendication 1.
22. Molécule d'acide nucléique selon la revendication 21, dans laquelle Z est une partie Fc d'une molécule d'anticorps.
- 40 23. Acide nucléique selon la revendication 21 ou 22, dans lequel X est le domaine 2 de type Ig du VEGF-R1 (Flt-1).
24. Acide nucléique selon la revendication 23, dans lequel la protéine de fusion comprend une séquence choisie dans le groupe constitué par SEQ ID NO : 8, 21 et 23.
- 45 25. Acide nucléique selon la revendication 23, dans lequel la protéine de fusion comprend une séquence choisie dans le groupe constitué par SEQ ID NO : 2 et 25.
- 50 26. Protéine de fusion selon la revendication 1, dans laquelle X est le domaine 2 de type Ig du VEGF-R1 (Flt-1) et la protéine de fusion comprend une séquence choisie dans le groupe constitué par SEQ ID NO 8, 21 et 23.
27. Protéine de fusion selon la revendication 1, dans laquelle X est le domaine 2 de type Ig du VEGF-R1 (Flt-1) et la protéine de fusion comprend une séquence choisie dans le groupe constitué par SEQ ID NO : 2 et 25.
- 55 28. Cellule de mammifère qui comprend l'acide nucléique selon l'une quelconque des revendications 21 à 25.
29. Cellule de mammifère selon la revendication 28, qui est une cellule humaine.

## EP 1 804 835 B9

30. Cellule de mammifère selon la revendication 29, qui est choisie dans le groupe constitué par un fibroblaste, un hépatocyte, une cellule endothéliale, un kératinocyte, une cellule hématopoïétique, un synoviocyte, une cellule épithéliale, une cellule rétinienne et une cellule souche.
- 5 31. Procédé *in vitro* qui comprend :
- la délivrance de l'acide nucléique selon l'une quelconque des revendications 21 à 25 à une cellule de mammifère isolée pour former une cellule qui exprime ladite protéine de fusion.
- 10 32. Procédé selon la revendication 31, dans lequel la protéine de fusion comprend une séquence choisie dans le groupe constitué par SEQ ID NO : 2, 8, 21, 23 et 25.
33. Procédé selon la revendication 31 ou 32, qui comprend en outre :
- 15 l'utilisation de la cellule qui exprime ladite protéine de fusion pour la fabrication d'une composition destinée à être délivrée à un mammifère.
34. Cellule de mammifère selon l'une quelconque des revendications 28 à 30, destinée à être utilisée pour traiter un mammifère.
- 20 35. Acide nucléique selon l'une quelconque des revendications 21 à 25, destiné à être utilisé pour traiter un mammifère, moyennant quoi ladite protéine de fusion est exprimée chez ledit mammifère.
36. Acide nucléique selon la revendication 35, dans lequel la protéine de fusion comprend une séquence choisie dans le groupe constitué par SEQ ID NO : 2, 8, 21, 23 et 25.
- 25 37. Cellule de mammifère selon la revendication 34 ou acide nucléique selon la revendication 35, le mammifère présentant une dégénérescence maculaire liée à l'âge humide ou une rétinopathie diabétique proliférative.
- 30 38. Cellule de mammifère selon la revendication 34 ou acide nucléique selon la revendication 35, le mammifère ayant le cancer.
39. Cellule de mammifère selon la revendication 34 ou acide nucléique selon la revendication 35, le mammifère souffrant de polyarthrite rhumatoïde.
- 35 40. Cellule de mammifère selon la revendication 34 ou acide nucléique selon la revendication 35, le mammifère souffrant d'asthme.
41. Cellule de mammifère selon la revendication 34 ou acide nucléique selon la revendication 35, le mammifère souffrant d'ostéoartrite.
- 40 42. Protéine de fusion selon l'une quelconque des revendications 1 à 8, destinée à être utilisée dans le traitement d'un mammifère.
- 45 43. Protéine de fusion selon la revendication 42, le mammifère présentant une dégénérescence maculaire liée à l'âge humide ou une rétinopathie diabétique proliférative.
44. Protéine de fusion selon la revendication 42, le mammifère ayant le cancer.
- 50 45. Protéine de fusion selon la revendication 42, le mammifère souffrant de polyarthrite rhumatoïde.
46. Protéine de fusion selon la revendication 42, le mammifère souffrant d'asthme.
47. Protéine de fusion selon la revendication 42, le mammifère souffrant d'ostéoartrite.
- 55 48. Protéine de fusion selon la revendication 42, la protéine de fusion comprenant une séquence choisie dans le groupe constitué par SEQ ID NO : 2, 8, 21, 23 et 25.

## EP 1 804 835 B9

**49.** Vecteur qui comprend l'acide nucléique selon l'une quelconque des revendications 21 à 25.

**50.** Vecteur selon la revendication 49, dans lequel le vecteur est un vecteur viral qui est choisi dans le groupe constitué par un vecteur adénoviral, un vecteur de virus adéno-associé, un vecteur rétroviral, et un vecteur lentiviral.

5

**51.** Vecteur selon la revendication 50, dans lequel le vecteur est un vecteur de virus adéno-associé.

**52.** Vecteur selon l'une quelconque des revendications 49 à 51, destiné à être utilisé pour traiter un mammifère.

**53.** Vecteur selon la revendication 52, le mammifère présentant une dégénérescence maculaire liée à l'âge humide ou une rétinopathie diabétique proliférative.

10

**54.** Vecteur selon la revendication 52, le mammifère ayant le cancer.

15

**55.** Vecteur selon la revendication 52, le mammifère souffrant de polyarthrite rhumatoïde.

**56.** Vecteur selon la revendication 52, le mammifère souffrant d'asthme.

**57.** Vecteur selon la revendication 52, le mammifère souffrant d'ostéoartrite.

20

25

30

35

40

45

50

55




FIG 1





FIG 2



**FIG 3**




Fig. 4




Fig. 5




Fig. 6




Fig.7




Fig. 8




Fig. 9




Fig.10




Fig. 11

# BIAcore binding kinetics for sFlt-1 molecules

Sensorgrams:





Table:

sFlt-1 molecule	$K_a$ (1/Ms)	$K_d$ (1/s)	$K_D$ (nM)
D2-9Gly-Fc	1.44e6	3.15e-4	2.19e-10
rFlt-1(Fc)(R&D)	2.71e6	1.22e-3	4.48e-10

The binding kinetics of the soluble Flt-1 were measured by surface plasmon resonance with a BIAcore instrument: sFlt-1 was immobilized onto a sensor chip, and VEGF165 was injected at concentrations ranging from 0.2 to 15 nM. The sensorgrams were evaluated using the BIA Evaluation program, the rate constants  $K_a$  and  $K_d$  were determined and the dissociation constant ( $K_D$ ) calculated from the ratio of  $K_d/K_a = K_D$ . The lower  $K_D$  value means better affinity.

FIG 12


**Bioactivity**



**FIG 13 B**


**Expression**

Fit ELISA (CM from tfect 3/18/06)



**FIG 13 A**

**Dimerization**



**FIG 13 C**

# Mouse OIR model




FIG 14

## REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

## Patent documents cited in the description

- US 5882877 A [0058]
- US 5670488 A [0058]
- WO 9633280 A [0058]
- WO 9640955 A [0058]
- WO 9725446 A [0058]
- WO 9529993 A [0058]
- WO 9700326 A [0058]
- WO 9957296 A [0060]
- US 6013516 A [0068]
- US 5994136 A [0068]
- US 5049386 A [0070]
- US 5279833 A [0070]
- US 5650096 A [0070]
- US 5747471 A [0070]
- US 5767099 A [0070]
- US 5910487 A [0070]
- US 5719131 A [0070]
- US 5840710 A [0070]
- US 5783565 A [0070]
- US 5925628 A [0070]
- US 5912239 A [0070]
- US 5942634 A [0070]
- US 5948925 A [0070]
- US 6022874 A [0070]
- US 5994317 A [0070]
- US 5861397 A [0070]
- US 5952916 A [0070]
- US 5948767 A [0070]
- US 5939401 A [0070]
- US 5935936 A [0070]
- US 5580859 A [0071]
- US 5963622 A [0071]
- US 5910488 A [0071]
- WO 60658209 A [0094]
- WO 60608887 A [0094]

## Non-patent literature cited in the description

- **Holash et al.** *Proc. Natl. Acad. Sci.*, 2002, vol. 99 (17), 11393-11398 [0005]
- **Vangelista et al.** *Protein Engineering*, 2002, vol. 15 (1), 51-57 [0005]
- **Sambrook et al.** *Molecular Cloning: A Laboratory Manual*. 1989 [0052]
- *Current Protocols In Molecular Biology*. 1987 [0052]
- *Oligonucleotide Synthesis*. 1984 [0052]
- *Animal Cell Culture*. 1987 [0052]
- *Methods In Enzymology*. Academic Press, Inc, [0052]
- *Handbook Of Experimental Immunology* [0052]
- *Gene Transfer Vectors For Mammalian Cells*. 1987 [0052]
- *PCR: the Polymerase Chain Reaction*. 1994 [0052]
- *Current Protocols In Immunology*. 1991 [0052]
- *Antibodies: A Laboratory Manual*. 1988 [0052]
- *PCR 2: A Practical Approach*. 1995 [0052]
- **Hurwitz, M.S. et al.** *Adenoviruses Virology*. Raven Press, 1996 [0056]
- **Hitt, M.M. et al.** *Adenovirus Vectors, The Development of Human Gene Therapy*. Cold Spring Harbor Laboratory Press, 1999 [0056]
- **Berkner, K.L.** *Curr. Top. Micro. Immunol.*, 1992, vol. 158, 39-66 [0057]
- **Jolly, D.** *Cancer Gene Therapy*, 1994, vol. 1, 51-64 [0057]
- **Kochanek et al.** *Proc. Natl. Acad. Sci. USA*, 1996, vol. 93, 5731-5736 [0058]
- **Parks et al.** *Proc. Natl. Acad. Sci. USA*, 1996, vol. 93, 13565-13570 [0058]
- **Lieber et al.** *J. Viral.*, 1996, vol. 70, 8944-8960 [0058]
- **Fisher et al.** *Virology*, 1996, vol. 217, 11-22 [0058]
- **Morrall et al.** *Hum. Gene Ther.*, 1998, vol. 10, 2709-2716 [0058]
- **Abruzzese et al.** *Hum. Gene Ther.*, 1999, vol. 10, 1499-507 [0060]
- **Muzyczka.** *Curr. Top. Micor. Immunol.*, 1992, vol. 158, 97-127 [0061]
- **Kotin et al.** *Proc. Natl. Acad. Sci.*, 1990, vol. 87, 2211-2215 [0062]
- **Ponnazhagan et al.** *Hum Gene Ther.*, 1997, vol. 8, 275-284 [0062]
- **Muzyczka, N.** *Curr. Top. Micor. Immunol.*, 1992, vol. 158, 97-129 [0064]
- **Miller.** *Nature*, 1992, vol. 357, 455-460 [0065]
- **Cristiano et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 11548 [0072]
- **Wu et al.** *J. Biol. Chem.*, 1994, vol. 269, 11542 [0072]
- **Wagner et al.** *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 6099 [0072]
- **Yoshimura et al.** *J. Biol. Chem.*, 1993, vol. 268, 2300 [0072]

- **Curiel et al.** *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 8850 [0072]
- **Kupfer et al.** *Human Gene Ther.*, 1994, vol. 5, 1437 [0072]
- **Gottschalk et al.** *Gene Ther.*, 1994, vol. 1, 185 [0072]
- **Auricchio.** *Mol. Ther.*, 2002, vol. 6, 490-494 [0073]
- **Bennett.** *Nature Med.*, 1996, vol. 2, 649-654 [0073]
- **Borrás.** *Experimental Eye Research*, 2003, vol. 76, 643-652 [0073]
- **Chaum.** *Survey of Ophthalmology*, 2002, vol. 47, 449-469 [0073]
- **Campochiaro.** *Expert Opinions in Biological Therapy*, 2002, vol. 2, 537-544 [0073]
- **Lai.** *Gene Therapy*, 2002, vol. 9, 804 813 [0073]
- **Pleyer.** *Progress in Retinal and Eye Research*, 2003, vol. 22, 277-293 [0073]
- **Smith.** *Investigative Ophthalmology & Visual Science*, 1994, vol. 35, 101-111 [0074]
- **Tobe.** *American Journal of Pathology*, 1998, vol. 153, 1641-1646 [0074]
- **Ambati.** *Nature Med.*, 2003, vol. 9, 1390-1397 [0074]
- **Karpus ; Schultz.** *Naturwiss*, 1985, vol. 72, 212-213 [0077]
- **Smith LEH ; Weslowski E ; McLellan A ; Kostyk SK ; D'Amato R ; Sullivan ; D'Amore PA.** Oxygen-Induced Retinopathy in the Mouse. *Invest Opth Vis Sci.*, 1994, vol. 35, 101-111 [0079]
- **Davis-Smyth et al.** *EMBO J.*, 1996, vol. 15, 4919 [0093]
- **Huston, J. S. et al.** *Methods Enzymol.*, 1991, vol. 203, 46-88 [0093]
- **Huston, J. S. et al.** *Proc. Natl. Acad. Sci. USA*, 1988, vol. 85, 5879-5883 [0093]
- **Johnson, S. et al.** *Methods Enzymol.*, 1991, vol. 203, 88-98 [0093]
- **Karpus, P. A. et al.** *Naturwiss.*, 1985, vol. 72, 212-213 [0093]
- **Keyt, B. A. et al.** *J. BioL Chem.*, 1996, vol. 271, 5638-5646 [0093]
- **Kortt, A. A. et al.** *Protein Engng*, 1997, vol. 10, 423-433 [0093]
- **Lee, Y-L. et al.** *Human Gene Therapy*, 1998, vol. 9, 457-465 [0093]
- **Mouz N. et al.** *Proc. Natl Acad Sci. USA*, 1996, vol. 93, 9414-9419 [0093]
- **Nielsen et al.** *Protein Eng.*, 1997, vol. 10, 1 [0093]
- **Qiu, H. et al.** *J. BioL Chem.*, 1998, vol. 273, 11173-11176 [0093]